EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0468	Vandaele Expert Report 4					Comparison of Dosage Strengths / Formulations of Brand Name PPIs prepared by LECG, LLC	
PTX0469	Vandaele Expert Report 5					Proton Pump Inhibitor (PPI) Quarterly Sales Revenue by Product 2Q01-1Q07 prepared by LECG, LLC	
PTX0470	Vandaele Expert Report 6				7/00/2006	Drug Class Review on Proton Pump Inhibitors	TVL 064258-064353
PTX0471	Vandaele Expert Report 7				1/00/2007	Consumer Reports Best Buy Drugs: Drugs to Treat Heartburn, Ulcers, and Stomach Acid Reflux: The Proton Pump Inhibitors-Comparing Effectiveness, Safety, and Price	TVL 064522-064535
PTX0472	Vandaele Expert Report 8				2005	Top 10 Selling Drugs In America from essense-of-life.com	TVL 064540-064551
PTX0473	Vandaele Expert Report 9				2007	DrugDigest, "Treatment Options, Proton Pump Inhibitors," https://www.drugdigest.org/DD /HC/HCDrugClass/0,4055,63-14,00.html	TVL 064536-064537
PTX0474	Vandaele Expert Report 10				6/14/2007	Treatment Options / Conditions & Treatments / Drug Digest: Antacids	TVL 064538-064539
PTX0475	Vandaele Expert Report 11				9/16/2002	Marketing, Product Differentiation, And Compensation in the Market for Antiulcer Drugs	TVL 064552-064600
PTX0476	Vandaele Expert Report 12				2007	"Gastroesophageal Reflux Disease in Infants and Children: Treatment Options," Journal of Pediatric Health Care, Online CME from Medscape, http://www.medscape.com/ viewarticle/458615 4	TVL 064601-064603
PTX0477	Vandaele Expert Report 13				11/00/1996	Now Available Without a Prescription From FDA website	TVL 064604-064609
PTX0478	Vandaele Expert Report 14				6/6/2002	The Wall Street Journal: Prilosec's Maker Switches Users to Nexium, Thwarting Generics	TVL 064610-064616
PTX0479	Vandaele Expert Report 15					Medical treatment of GERD from barrettsinfo.com	TVL 064617-064619
PTX0480	Vandaele Expert Report 16					HelpHeartburn.com article: Heading off Heartburn	TVL 064620-064623
PTX0481	Vandaele Expert Report 17				6/22/2002	The Wall Street Journal: Federal Panel Backs Prilosec for Over-the-Counter Sales	TVL 064676-064678
PTX0482	Vandaele Expert Report 18				11/00/2001	Prescription Drugs and Mass Media Advertising, 2000	TVL 064761-064777
PTX0483	Vandaele Expert Report 19				2003	Prilosec OTC-How Does It compare to Zantac 75, Pepcid AC, and Other Over-The-Counter Heartburn Remedies? When to Use Prilosec OTC. From medicationsense.com	TVL 064668-064675

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 1 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0484	Vandaele Expert Report 20				10/00/2002	Harvard Business School Marketing Research Papers: Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products	TVL 064715-064760
PTX0485	Vandaele Expert Report 21				6/00/2003	Demand Effects of Recent Changes in Prescription Drug Promotion	TVL 064679-064714
PTX0486	Vandaele Expert Report 22				2004	The $800 Million Pill: The Truth behind the Cost of New Drugs (from ucpress.edu)	TVL 064785-064809
PTX0487	Vandaele Expert Report 23				10/1/2004	The Big Squeeze (from pharmexec.com)	TVL 064778-064784
PTX0488	Vandaele Expert Report 24				2007	Orange Book Detail Record Searches for various drugs	TVL 064810-064845
PTX0489	Vandaele Expert Report 25					The Prescription Generic Omeprazole DTC Launch	TVL 064846-064851
PTX0490	Vandaele Expert Report 26				9/22/2003	Prilosec OTC Launch Off and Running; Strongest Start Of Any New P&G Brand Ever (from pginvestor.com)	TVL 064852
PTX0491	Vandaele Expert Report 27				9/26/2006	Zegerid Presentation- Santarus Investor Meeting Slides	TVL 064881-064905
PTX0492	Vandaele Expert Report 28				5/23/2007	Zegerid Presentation-Santarus Investor Meeting Slides, May 22-23, 2007, http://phx.corporate-ir.netlphoenix.zhtml? c=175502&p=irol-presentations	TVL 064853-064880
PTX0493	Vandaele Expert Report 29				5/1/2007	Santarus Reports First Quarter 2007 Financial Results	TVL 064906-064908
PTX0494	Vandaele Expert Report 30					Prevacid 1995-2006 Historical Units / Gross Sales / Net Sales (Historical ACT.xls)	
PTX0495	Vandaele Expert Report 31					Prevacid 2004-2006 Product Line P & L.xls	
PTX0496	Vandaele Expert Report 32				3/00/2007	Top 10 Products and market Trends for Sandi 050907.xls	
PTX0497	Vandaele Expert Report 33				2006	Prices, Profits, and Innovation: Examining Criticisms Of New Psychotropic Drugs' Value (from Health Affairs)	TVL 064930-064940
PTX0498	Vandaele Expert Report 34				6/15/2006	Signa HealthCare Coverage Position: Proton Pump Inhibitor Therapy	TVL 064941-064950
PTX0499	Vandaele Expert Report 35				2002	Returns on Research and Development for 1990s New Drug Introductions (from Pharmacoeconomics)	TVL 064951-064969
PTX0500	Vandaele Expert Report 36				9/24/1984	Drug Price Competition and Patent Term Restoration Acto for 1984	TVL 064970-064991
PTX0501	Vandaele Expert Report 37				7/00/1998	Congressional Budget Office Study: How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry	TVL 064992-065077

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 2 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0502	Vandaele Expert Report 38				1996	Industry Structure, Strategy, and Public Policy Chapter 9: Pharmaceuticals	TVL 065078-065134
PTX0503	Vandaele Expert Report 39				7/15/2004	Generic Pharmaceutical Industry Review; Executive Summary	TVL 065135-065190
PTX0504	Vandaele Expert Report 40				5/00/1995	Information, Marketing, and Pricing in the US Antiulcer Drug Market *(from The American Economic Review)*	TVL 065191-065197
PTX0505	Vandaele Expert Report 41				4/00/1999	Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs *(from Journal of Law and Economics)*	TVL 065198-065212
PTX0506	Vandaele Expert Report 42				1996	Department of Agricultural & Resource Economics, UCB; Higher Prices form Entry: Pricing of Brand-Name Drugs	TVL 065213-065253
PTX0507	Vandaele Expert Report 43				9/00/2004	The Journal of Industrial Economics: What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs?	TVL 065254-065285
PTX0508	Vandaele Expert Report 44				11/00/2001	Prescription Drug Trends: A Chartbook Update	TVL 065287-065358
PTX0509	Vandaele Expert Report 45				11/22/2004	"Rx Marketing Sepnd Does Exceed R&D", AstraZeneca EO Says", "The Pink Sheet"-article on R & D versus Marketing spending	TVL 065286
PTX0510	Vandaele Expert Report 46				7/6/2000	The Wall Street Journal: Drug Firms, Stymied in the Lab, Become Marketing Machines	TVL 065359-065365
PTX0511	Vandaele Expert Report 47				1997	Pharmaceutical Economics and Policy pp. 53-54	TVL 065366-065369
PTX0512	Vandaele Expert Report 48				1/17/2002	The Long Shadow of Patent Expiration: Generic Entry and RX to OTC Switches	TVL 065370-065418
PTX0513	Vandaele Expert Report 49				2004	Pharmaceutical Overview-Executive's Guide 2004	TVL 065419-065423
PTX0514	Vandaele Expert Report 50				2007	Chapter 9-The Untied States' Experience with Direct-to Consumer Advertising of Prescription Drugs: What Have We Learned?	TVL 065424-065456
PTX0515	Vandaele Expert Report 51				4/4/2005	Direct to Consumer Advertising and Prescription Choice	TVL 065457-065476
PTX0516	Vandaele Expert Report 52				2005	The Effect of Prescription Drug Advertising on Doctor Visits	TVL 065477-065504
PTX0517	Vandaele Expert Report 53					Prevacid Promotional Expenses Historical.xls	
PTX0518	Vandaele Expert Report 54				2006	Colitis due to Clostridium difficile toxins: under diagnosed, highly virulent, and nosocomial	TVL 065505-065514
PTX0519	Vandaele Expert Report 55					"Managed Care Systems Educational Research Report," Healthcare Performance Consulting and CME Enterprise	TVL 065515-065538
PTX0520	Vandaele Expert Report 56				5/00/2003	IMS Review: Steady But Not Stellar (MM & M)	TVL 069320-069324

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 3 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0521	Vandaele Expert Report 57				1990	Industrial Market Structure and Economic Performance: Advertising, Image and Monopoly Power (pp. 580-592)	TVL 065548-065562
PTX0522	Vandaele Expert Report 58				3/10/2006	Entry order as a consideration for innovation strategies (Nature Reviews Drug Discovery)	TVL 065539-065547
PTX0523	Vandaele Expert Report 59				10/22/2002	Persistence in prescriptions of branded drugs (International Journal of Industrial Organization)	TVL 065596-065613
PTX0524	Vandaele Expert Report 60				2/24/1999	Network Effects and Diffustion in Pharmaceutical Markets: Antiulcer Drugs	TVL 065563-065595
PTX0525	Vandaele Expert Report 61					A Homerun for American Home (An MM&M Corporate Profile)	TVL 065619-065624
PTX0526	Vandaele Expert Report 62				10/00/2004	Commercial and Pipeline Perspectives: Upper GI Disorders (from piribo.com)	TVL 065614-065618
PTX0527	Vandaele Expert Report 63				11/002003	Takeda Abbott Pharmaceuticals (TAP) In 2002	TVL 069337-069352
PTX0528	Vandaele Expert Report 64				7/00/2001	Pharmacy Benefits Management Strategic Healthcare Group Medical Advisory Panel Abbreviated Drug Class Review: Proton Pump Inhibitors	TVL 069325-069336
PTX0529	Vandaele Expert Report 65				7/00/2001	Esomeprazole (Nexium): A New Proton Pump Inhibitor (The Cleveland Clinic Center for Continuing Education)	TVL 069317-069319
PTX0530	Vandaele Expert Report 66				4/00/2007	BlueCross BlueShield of Nebraska "Proton Pump Inhibitors Preauthorization Criteria"	TVL 069311-069316
PTX0531	Chambliss 1					Chambliss CV	
PTX0532	Chambliss 5					U.S. Patent 5,045,321	TVL 0010962-010972
PTX0533	Chambliss 6					Sections of the ANDA produced as TVL 006613-006624 and 006835-006847	BYRN 00032-00056
PTX0534	Chambliss 8				1985	The United States Pharmacopeia, The National Formulary	TVL 059558-059564
PTX0535	Chambliss 11					Particle Size Conversion Chart from sigmaalrich.com	
PTX0536	Chambliss 14					Chemical Stability of Pharmaceuticals Chapter 1 pp. 3-6	TVL 0063860-0063885
PTX0537	Chambliss 15				1985	*Development of an oral formation of omeprazole Gastro Scand J Gastroenterol 1985; 20(suppl 108): 113-120*	TVL 059548-059558
PTX0538	Chambliss 16				1985	Omeprazole: A Study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage *Gastro 88:64-69 (1985)*	TVL 065992-065998

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 4 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0539	Chambliss 17				1976	Kinetic analysis of penicillin degration in acidic media *J Pharma Sci 65: 1165-1170 (1976)*	TVL 065978-065984
PTX0540	Chambliss 18				1980	*Journal of Pharmaceutical Sciences, Vol. 69, No. 4, April 1980, 410-413*	TVL 063845-063848
PTX0541	Chambliss 19				1983	*Pharmaceutical Technology, September 1983*	TVL 065972-065977
PTX0542	Chambliss 20				1929	The theory and practice of industrial pharmacy pp. 36-37	TVL 065988-065991
PTX0543	Chambliss 21				1975	*Remington's Pharmaceutical Sciences, Chapter 81, 1423-1423*	TVL 063886-063888
PTX0544	Chambliss 22					*Pharmaceutical Pelletization Technology, p. 226*	TVL 063839-063841
PTX0545	Chambliss 23				1984	Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H + K)-ATPhase within the parietal cell *Biochimico et Bio Acta 778: 549-558*	TVL 063980-063989
PTX0546	Chambliss 24					U.S. Patent 4,628,098	TVL 010937-010943
PTX0547	Chambliss 25					U.S. Patent 4,686,230	TVL 011082-011106
PTX0548	Chambliss 26					U.S. Patent 4,255,431	TVL 011020-011029
PTX0549	Chambliss 27					Japanese Patent Appln Publn No. 19715/85	TAKEDA 681580-681598
PTX0550	Chambliss 28				1998	*British Pharmacopoeia, 1998, Vol. 1, 694-695*	
PTX0551	Chambliss 30					Declaration under Rule 132 of Shin-ichior Hirai re: application Tadashi Makino	TAKEDA 739677-739680
PTX0552	Chambliss 31					The Theory and Practice of Industrial Pharmacy Chapter 8: Preformulation, *pp 171, 193-194*	
PTX0553	Chambliss 32					*Gastroenterology, 1986, Chapter 6, 115 - 283 (cover page shows production number TVL 059548)*	AMIDON 00238-00269
PTX0554	Chambliss 33					*Gastroenterology, 114 - 120*	TVL 059548-059557
PTX0555	Fennerty 2					Efficacy and safety in the treatment of erosive reflux esophagitis *Am J Gastro 91:1749-1757 (1996)*	
PTX0556	Fennerty 3				2003	Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic disease *Aliment Pharmacol Ther 18:559-568 (2003)*	
PTX0557	Fennerty 5				2007	Prevacid package insert	FENNERTY 00486-00521
PTX0558	Fennerty 6				2005	Prilosec pharmaceutical information	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 5 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0559	Fennerty 7				1999	Safety profile of the proton pump inhibitors *Am J Health-Sys Pharm 56:S11-S17 (1999)*	
PTX0560	Fennerty 8				2001	*The American Journal of Gastroenterology, Vol. 96, No. 11, 2001, 3089-3098*	
PTX0561	Fennerty 9				2007	*Best Practice and Research Clinical Gastroenterology, Vol. 21, No. 4 pp. 609-631, 2007*	
PTX0562	Fennerty 10				2007	Drug Class Review on Proton Pump Inhibitors - Final Report - July 2007	
PTX0563	Fennerty 11					Fennerty CV	
PTX0564	Kaunitz 2					CV of Jonathan Kaunitz	
PTX0565	Amidon 2					U.S. Patent 5,045,321	TVL 100962-010972
PTX0566	Amidon 4				1/31/1985	Japanese patent filing number S58-125593	TVL 681580-681598
PTX0567	Takeda Claim Construction 5					USPTO search for "pharmaceutical composition" done 09/11/2007	
PTX0568	Takeda Claim Construction 6					Random House Dictionary definitions of "contact"	
PTX0569	Bugay 3					Bugay Supplemental Production	BUGAY 000196.001-BUGAY 000196.050
PTX0570	Cole 01				2007	Sample Analysis Sheets	HIRT 048-070
PTX0571	Wolfe 02				4/11/2007	Lab Notebook BPG-07-012	TVL 069861-069863
PTX0572	Wolfe 03				2007	Sample Analysis Sheets	HIRT 048-068
PTX0573	Wolfe 03A				2007	Sample Analysis Sheets	HIRT 051-069
PTX0574	Sunberg 64				12/9/1986	U.S. Patent 4,628,098	TVL 010937-010943
PTX0575	Sunberg 66					Prevacid 1996-2006 Historical Units/Gross Sales/Net Sales	TAP 0273338
PTX0576	Sunberg 67					Prevacid Lansoprazole - Power Plus Versatility	TAP 0273713-0273720
PTX0577	Sunberg 68				10/10/04	Memo from Judy Decker Wargel (TAP) re: Lansoprazole/Letter from FDA	TAP 000315-000314
PTX0578	Sunberg 69				11/7/94	Memo from Jennifer Ackerman (Abbott) re: call to FDA	TAP 000552
PTX0579	Sunberg 70					Prevacid Lansoprazole - The Full Service Pump	TAP 0273581-0273602
PTX0580	Sunberg 71				4/16/91	Draft minutes of TAP R&D committee meeting, Takeda research 3114, Osaka, Japan	TAKEDA 493766-493772
PTX0581	Sunberg 72				9/3/91	U.S. Patent 5,045,321	TVL 010962-010972
PTX0582	PX1				2001	Organizational structure	TVL 059946
PTX0583	PX3				9/3/1991	U.S. Patent 5,045,321	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 6 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0584	PX4				7/15/2002	ANDA for Lansoprazole D. R. Capsules 15 mg and 10 mg Section XI.2 Manufacturing ad Processing Instructions: Commercial Batch Records	TVL 006849-006907
PTX0585	PX5				9/7/2002	Email from Di Capua re: Lansoprazole SEM	TVL 052763
PTX0586	PX6				9/7/2004	ANDA for Lansoprazole D. R. Capsules 15 mg and 10 mg Section XV.2 Drug Product	TVL 007574-007594
PTX0587	PX7				9/29/2005	U.S. Patent Application Publication 2005/0214371 A1	
PTX0588	PX8				9/29/2005	U.S. Patent Application Publication2005/0214372 A1	
PTX0589	Erickson-2				8/27/2004	Application for a New Drug for Lansoprazole Delayed Release Capsules, USP 15 mg and 30 mg	TVL 000001-000021
PTX0590	Erickson-3					Section VI Bioailability/Bioequivalence	TVL 000223-000261
PTX0591	Erickson-4					Teva ANDA 77-255 Lansoprazole Delayed-Release Capsules USP, 15mg and 30mg	TVL 008271-008293
PTX0592	Erickson-5				12/14/2006	Minor Amendment to the ANDA 77-255 Lansoprazole Delayed Release Capsules USP, 15mg and 30mg, response to a March 22, 2006 Review Letter	TVL 062439-052502
PTX0593	Erickson-6				2/6/2006	Bioequivalency Amendment for ANDA 77-255 letter from FDA to Teva	
PTX0594	Erickson-7				1/17/2007	Teva submission of a labeling amendment for ANDA 77-255 15mg and 30mg	TVL 062503-062508
PTX0595	DX2				12/9/1986	U.S. Patent 4,628,098	
PTX0596	DX3				9/3/1991	U.S. Patent 5,045,321	
PTX0597	DX7				9/3/2001	U.S. Patent 5,045,321	
PTX0598	DX8				9/3/2001	File History for U.S. Patent 5,045,321	TAKEDA 422696-423088
PTX0599	DX10				06/00/92	History on Formulation and Manufacturing Procedure for AG-1749 Capsules by Jun-ichi Kikuta	TAKEDA 601019-601043
PTX0600	DX11				6/3/1985	Monthly report by Hirai	TAKEDA 610685
PTX0601	DX12				7/31/1985	Monthly report	TAKEDA 610684
PTX0602	DX13				12/2/1985	Monthly report	TAKEDA 047455-047456
PTX0603	DX14				12/25/1985	Monthly report	TAKEDA 610681
PTX0604	DX15				8/6/1986	Monthly report	TAKEDA 047535-047536
PTX0605	DX16				12/9/1986	U.S. Patent 4,628,098 with certificates of correction and extension of patent term	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 7 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0606	DX17				3/10/1981	U.S. Patent 4,255,431 with certificates of correction and extension of patent term	
PTX0607	DX18				9/18/1984	U.S. Patent 4,472,409	
PTX0608	DX19					Various monthly reports	TAKEDA 040986-040992
PTX0609	DX20				09/00/83	Monthly report	TAKEDA 040858-040865
PTX0610	DX21				10/00/83	Monthly report	TAKEDA 040866-040873
PTX0611	DX22				11/00/83	Monthly report	TAKEDA 040874-040882
PTX0612	DX23				07/00/84	Monthly report	TAKEDA 040936-040942
PTX0613	DX24				08/00/84	Monthly report	TAKEDA 040943-040950
PTX0614	DX25				09/00/84	Monthly report	TAKEDA 040951-040957
PTX0615	DX26				00/00/89	Antisecretory and Antiulcer Activities of a Novel Proton Pump Inhibitor AG-1749 in Dogs and Rats	TVL 059756-059765
PTX0616	DX27				2/13/1986	Application number 61-29567	
PTX0617	DX27A					Page pulled out from DX27	TAKEDA 422781
PTX0618	DX28				2/21/1986	Application number 61-38059	
PTX0619	DX28A					Page pulled from DX28	TAKEDA 422831
PTX0620	DX29				12/27/1985	Monthly report	TAKEDA 047495
PTX0621	DX30				10/0090	Chem. Pharm. Bull. Vol. 38(10) pp. 2853-2858	TAKEDA 015682-015687
PTX0622	DX31					Monthly reports	TAKEDA 040883-040890
PTX0623	DX32				11/2/1988	Declaration of Shinichiro Hirai submitted for the '321 Patent	HAM 003522-003525
PTX0624	DX33				6/28/1988	Amendment submitted to USPTO by Helmuth Wegner	HAM 003515-003521
PTX0625	DX34				3/27/1990	Reply brief submitted by Harold Wegner and Douglas Mueller received by USPTO on 03/27/90	
PTX0626	DX35				05/30-06/19/91	Certificate of Experimental Results	TAKEDA 380476-380488
PTX0627	DX36					AG Sample Table AG1-2352	TAKEDA 060988-061262
PTX0628	DX37				12/9/1986	U.S. Patent 4,628,098 file history	TVL 008405-008546
PTX0629	DX38				09/00/83	Monthly report	TAKEDA 040858-040865
PTX0630	DX39				09/00/83	Translation of DX38	TAKEDA 040858-040865
PTX0631	DX40					Lab notebook	TAKEDA 642642-642825
PTX0632	DX41					Drawing of a compound by witness	
PTX0633	DX42					Lab notebook	TAKEDA 445983-446084
PTX0634	DX43					Lab notebook	TAKEDA 446085-446188

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 8 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0635	DX44					Lab notebook	TAKEDA 446189-446291
PTX0636	DX45					Lab notebook	TAKEDA 446189-446291
PTX0637	DX46					Lab notebook	TAKEDA 446292-446396
PTX0638	DX47					Lab notebook	TAKEDA 446397-446501
PTX0639	DX48					Lab notebook	TAKEDA 446502-446505
PTX0640	DX49					Lab notebook	TAKEDA 446606-446709
PTX0641	DX50					Lab notebook	TAKEDA 446710-446813
PTX0642	DX51					Lab notebook	TAKEDA 446814-446916
PTX0643	DX52					Lab notebook	TAKEDA 446917-447024
PTX0644	DX53					Lab Notebook	TAKEDA 039372-039476
PTX0645	DX54					Lab Notebook	TAKEDA 039477-039581
PTX0646	DX55					Lab Notebook	TAKEDA 0039582-039685
PTX0647	DX56					Lab Notebook	TAKEDA 039686-039789
PTX0648	DX57					Lab Notebook	TAKEDA 039790-039893
PTX0649	DX58					Lab Notebook	TAKEDA 039894-040000
PTX0650	DX59					Lab Notebook	TAKEDA 040001-040114
PTX0651	DX60					Lab notebook	TAKEDA 638639-638797
PTX0652	DX62					Notebook 1753	TAKEDA 638798-638966
PTX0653	DX63					Notebook 2155	TAKEDA 649039-649161
PTX0654	DX64					Notebook 2624	TAKEDA 639072-639163
PTX0655	Mueller 1				11/28/1988	Letter Accompanying Amendment for Serial No. 014,303 ('321) with Hirai declaration dated 11/02/88	HAM 003514-003525
PTX0656	Fackler 10				12/9/1986	U.S. Patent 4,628,098 with certificates of correction and certificate extending patent term	
PTX0657	Fackler 12				12/5/2005	Paragraph IV Certification Letter	TVL 028243-028254
PTX0658	Fackler 13				7/28/2003	Email from Paul Fackler to Gregg DeRosa Re: Lansoprazole	TVL 046731-046733
PTX0659	Fackler 14				7/4/2001	Letter from Berta Iosefzon to Julia Hrakovsky Re: SEM Characterization of Prevacid (Lansoprazole) Capsules 30mg	TVL 028941-028946; 028948-028953
PTX0660	Fackler 15				11/25/2004	Email from Dvora Zilber to Marie-Silve Boutin Re: Lansoprazole answer	TVL 034143-034154
PTX0661	Fackler 16					Lansoprazole DR 30 mg Capsules Batch Summary chart	TVL 035179-035182; 035184
PTX0662	Fackler 17				7/8/2004	Summary of Stability Studies from ANDA	TVL 007716-007717

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 9 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0663	Seely 73				11/5/1987	Minutes from the October 21 Meeting with FDA	TAP 0274540-0274543
PTX0664	Seely 74				12/12/1994	Letter from Takeda to TAP	TAKEDA 554515
PTX0665	Seely 75				5/13/1994	Letter from John Seely (TAP) to Kiyoshi Kitazawa (Takeda)	TAKEDA 546936
PTX0666	Seely 76				8/9/1990	Minutes from 08/09/90 FDA Meeting	TAP 0227323-0227325
PTX0667	Seely 77				4/20/1995	Fax from John Seely (TAP) to Kiyoshi Kitazawa (Takeda)	TAP 0194492-0194493
PTX0668	Seely 78				9/18/1989	Memo from Judy Decker Wargel (Takeda) Re: Lansoprazole/End of Phase II Meeting	TAP 0274559-0274564
PTX0669	Wegner 100					File History for U.S. Patent 5,045,321	TAKEDA 739426-739858
PTX0670	Wegner 102					File History for U.S. Patent 4,628,098	TAKEDA 422543-422695
PTX0671					11/22/1988	U.S. Patent 4,786,505	
PTX0672					8/1/1989	U.S. Patent 4,852,320	
PTX0673					4/19/1995	FDA Letter to TAP acknowledging change of corporate name	TAP 0000001
PTX0674					1998	Prevacid promotional material "Have a rough stay..."	TAP 0273505-0273524
PTX0675					1998	Prevacid promotional material "When choosing a pump..."	TAP 0273525-0273548
PTX0676					1996	Prevacid promotional material "On the Road to Recovery..."	TAP 0273549-0273556
PTX0677					1999	Prevacid promotional material "Choose Full Service..."	TAP 0273557-0273576
PTX0678					1999	Prevacid promotional material "The Full Service Pump..."	TAP 0273577-0273580
PTX0679						Prevacid promotional material "Comparing lansoprazole and omeprazole..."	TAP 0273643-0273646
PTX0680					2002	Prevacid promotional material "For power plus versatility.."	TAP 0273647-0273650
PTX0681					2002	Prevacid promotional material "Prevacid Provides Power plus Versatility..."	TAP 0273651-0273654
PTX0682					2002	Prevacid promotional material attaching Am. J. Gastroenterology article	TAP 0273655-0273669
PTX0683					2003	Lansoprazole promotion attaching Clin. Drug. Investigation article	TAP 0273738-0273755
PTX0684						Prevacid promotional material "Do you have the stomach for a new proton pump inhibitor?"	TAP 0273756-0273775
PTX0685					2005	Prevacid promotional material "Prevacid in a hospital setting..."	TAP 0273826-0273833
PTX0686					2006	Prevacid promotional material attaching Arch. Intern Med article	TAP 0273834-0273837
PTX0687	Hirt 4				7/12/2007	letter from Cole	
PTX0688	Hirt 3					email	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 10 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0689	DAJANI 1					Dajani CV	
PTX0690	DAJANI 2					Ulcer Diseases	
PTX0691	DAJANI 3					AFFIDAVIT BY DR. HOPFINGER.	
PTX0692	DAJANI 4					FIRST DECLARATION OF GEORGE C FULLER	
PTX0693	DAJANI 5					EUROPEAN PATENT APPLICATION 0174726	
PTX0694	DAJANI 6					U.S. PATENT 4,628,098	
PTX0695	DAJANI 7					U.S. PATENT 3,950,537	
PTX0696	DAJANI 8					U.S. PATENT 5,679,375	
PTX0697	DAJANI 9				1979	Synergistic actions of propantheline bromide with cimetidine and thiopropazate hydrochloride in the prevention of stress ulcer formation in rats. *JPET 210: 373-377*	
PTX0698	DAJANI 10				1999	"[] A Novel, Orally Effective Cannabinoid with Analgesic and Anti-inflammatory Properties" JPET vol 291:31-38	
PTX0699	DAJANI 12					Takeda IMAU raw data produced at TAKEDA 642777-642781 with translation	WHITTLE 001916 - 1926
PTX0700	DAJANI 14					Takeda IMAU raw data produced at TAKEDA 642785 with translation	WHITTLE 1927 - WHITTLE 1929
PTX0701	DAJANI 15					Log paper graphs by Whittle	WHITTLE 547 - 562
PTX0702	DAJANI 17					Organix, Inc. letter with attached documents	
PTX0703	DAJANI 18					Eurolinks Product Safety Labs Evaluation of Compounds A and B	
PTX0704	DAJANI 19					U.S. Patent application 2005/0020638	
PTX0705	DAJANI 21					CHAPTER 27 Textbook of Organic Medicinal and Pharmaceutical Chemistry	
PTX0706	DAJANI 23					CHAPTER FIVE Halogenated Hydrocarbons from Textbook of Organic Medicinal and Pharmaceutical Chemistry	
PTX0707	DAJANI 24				1974	Fluorinated compounds of medicinal interest *Chemtech pp. 752-757 (1974)*	
PTX0708	DAJANI 25				07/00/1992	Drugs for Treatment of Peptic Ulcers *J Assoc Academic Minority Physicians Vol 3:78-88*	
PTX0709	DAJANI 26				12/6/2006—12/8/2006	Table 1: Effect of Compound C (0-5346) Against Indomethacin Induced Gastric Antal Lesions	PSL 000462- 000465
PTX0710						Spreadsheet	KAUNITZ 0001376-00

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 11 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0711						Spreadsheet	KAUNITZ 0001377-00-0001377-01
PTX0712						Spreadsheet	KAUNITZ 0001378-00-0001378-05
PTX0713						Spreadsheet	KAUNITZ 0001379-00-0001379-01
PTX0714						Spreadsheet	KAUNITZ 0001380-00-0001380-05
PTX0715						PSL2.pzf	KAUNITZ 0001381
PTX0716						Spreadsheet, Prevacid Historical Unit/Gross Sales/Net Sales 1995-2006	TAP 0437176-0437178
PTX0717						Spreadsheet, Competitive Product Profiles	TAP 0437183-0437188
PTX0718						Spreadsheet, leading 20 Products by U.S. Sales, MAT 11/01-11/06	TAP 0437189-0437206
PTX0719						Spreadsheet, Trends by Specialty for Prevacid 2006-2007	TAP 0437207-0437247
PTX0720						Spreadsheet, Top Products by U.S. Sales 2002-2006	TAP 0437248-0437269
PTX0721						Spreadsheet, Prevacid Line P&L 2004-2006	TAP 0437270-0437271
PTX0722						Spreadsheet, Sales Force Alignment, Headcount Summary 2006-2007 Plans	TAP 0437466-0437563
PTX0723						Spreadsheet, Proton Pump Inhibitors Cost/Contact, Samples 1996-2003	TAP 0437564-0437595
PTX0724						Spreadsheet, Prevacid Share of Anti-Ulcer Market 1995-1998	TAP 0437596
PTX0725						Spreadsheet, Verispan SFSS 1995-2000	TAP 0437597-0437600
PTX0726						Spreadsheet, Prevacid Promotional Expenses 1995-2006	TAP 0437616
PTX0727						Spreadsheet, Prevacid Summary Departmental Expenses For 12 Months Ending Dec. 31 2001-2006	TAP 0437617-0437637
PTX0728						Spreadsheet, Prevacid Summary Departmental Expenses For 12 Months Ending Dec. 31 1995-2000	TAP 0437638-0437649
PTX0729						Spreadsheet, PPI Market TRx Volume 1996-2000	TAP 0437650-0437659
PTX0730					1/17/2006	Complaint	Docket # 1
PTX0731					7/10/2007	Teva Pharmaceuticals USA, Inc.'s AND Teva Pharmaceutical Industries LTD.'s Amended Answer, Defenses, And Counterclaims To Amended Complaint	Docket # 121

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 12 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0732					7/24/2007	Takeda Pharmaceutical Company, LTD.'s And TAP Pharmaceutical Products Inc.'s Reply To Teva Pharmaceuticals USA, Inc.'s And Teva Pharmaceutical Industries LTD.'s Amended Counterclaims To Amended Complaint	Docket # 123
PTX0733					6/13/2006	Amended Complaint	Docket # 36
PTX0734					2/6/2006	Teva Pharmaceuticals USA, Inc.'s Answer, Defenses, And Counterclaims	Docket # 9
PTX0735					4/10/2006	Defendant Teva Pharmaceuticals USA, Inc.'s Responses And Objections To TAP Pharmaceutical Products, Inc.'s First Set Of Interrogatories	
PTX0736					8/11/2006	Defendant Teva Pharmaceuticals USA, Inc.'s Supplemental Responses To Interrogatory Nos. 7 And 8 Of Plaintiff TAP Pharmaceutical Products, Inc.'s First Set Of Interrogatories	
PTX0737					12/12/2006	Defendant Teva Pharmaceuticals USA, Inc.'s And Teva Pharmaceutical Industries LTD.'s Supplemental Responses And Objections To TAP Pharmaceutical Products, Inc.'s Interrogatory No. 3	
PTX0738					1/18/2007	Defendant Teva Pharmaceuticals USA, Inc.'s And Teva Pharmaceutical Industries LTD.'s Responses To Takada Pharmaceutical Company, LTD.'s First Requests For Admission (NOS. 1-3)	
PTX0739					2/23/1993	European Prosecution History EPO174726PH	
PTX0740	Byrn 4					U.S. Patent 5,045,321	
PTX0741	Byrn 6					File history for U.S. Patent 5,045,321	TAKEDA 739426-739858
PTX0742	Bryn Production					Page with handwriting created by Dr. Byrn at deposition	BYRN 000258
PTX0743						Manufacturing and Processing Instructions	TVL 0006835-007023
PTX0744	Chambliss Rebuttal Docs Considered				2006	*Oregon Health & Science University's Drug Class Review on Proton Pump Inhibitors, July 2006*	
PTX0745	Chambliss 2nd Docs Considered					Manufacturing Steps from Teva's ANDA	
PTX0746	Chambliss 2nd Docs Considered					*Handbook of Pharmaceutical Excipients, Electronic Version, 2004*	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 13 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0747	Chambliss 2nd Docs Considered					http://www.sigmaaldrich.com/Area_of Interest/Research_Essentials/Chemicals/Key_Res ources/Technical _Library/Particle_Size_Conversion.html	
PTX0748	Chambliss First Docs Considered				1992	Stabilization of a new antiulcer drug (Lansoprazole) in the solid dosage forms *Drug Dev Ind Pharm 18(13):1437-1447*	
PTX0749	Chambliss First Docs Considered					TAKEDA-355232-39	TAKEDA-355232-39
PTX0750	Chambliss First Docs Considered					TAKEDA-681588-98	TAKEDA-681588-98
PTX0751	Chambliss First Docs Considered				2007	Microenvironmental pH Modulation in Solid Dosage Forms, J. PHARM. SCI. 96:5	
PTX0752	Chambliss First Docs Considered				1989	Formulation Variables, PHARMACEUTICAL PELLITIZATION TECHNOLOGY	
PTX0753	Chambliss First Docs Considered				1975	Stability of Pharmaceutical Products, REMINGTON'S PHARMACEUTICAL SCIENCES, 15th Edition	
PTX0754	Chambliss First Docs Considered					U.S. Patent 4,666,919	
PTX0755	Dajani Docs Considered				1965	*Degraded carageenan and duodenal ulceration in the guinea pigs. Nature 206: 101-102*	
PTX0756	Dajani Docs Considered				1966	*The mechanism of gastric hyperacidity produced by pyloric ligation in the rat. Am J Dig Dis 11: 231-241*	
PTX0757	Dajani Docs Considered				1971	*Antiulcer activity of gastric irritants in the Shay rat test. Unpublished document, Rohm & Hass Research Laboratory, Springhouse, Pennsylvania*	
PTX0758	Dajani Docs Considered				1978	*Effects of E-prostaglandins on canine gastric potential difference. Dig Dis Sci 23:436-442*	
PTX0759	Dajani Docs Considered				1979	*Synergistic actions of propantheline bromide with cimetidine and thiopropazate hydrochloride in the prevention of stress ulcer formation in rats. J Pharmacol Exp Therap 210: 373-377*	
PTX0760	Dajani Docs Considered				1956	*Steroids. In: Textbook of Organic Medicinal and Pharmaceutical Chemistry. Edited by CO Wilson and Gisvold O.JB Lippincott Company, Philadelphia, Pennsylvania, pp 568-598*	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 14 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0761	Dajani Docs Considered				1981	*Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibition gastric acid secretion.*	
PTX0762	Dajani Docs Considered				1959	*Gastrointestinal pharmacology of antipyretic-analgesic agents. I. Effects on acid secretion and ulcer formation in the Shay rat. Arch Int Pharmacodyn Ther 119: 389-397*	
PTX0763	Dajani Docs Considered				1983	*Stress ulcers. In: Gastrointestinal Disease. Pathophysiology, Diagnosis and Management. Edited by Sleisenger MH, Fordtran JS. Third Edition, Volume I. W.B Saunders and Company, New York, New York, pp 612-625*	
PTX0764	Dajani Docs Considered				1958	*Ulcerogenic properties of steroids. Proc Soc Exp Biol Med 99: 443-447*	
PTX0765	Dajani Docs Considered				1956	The incidence of peptic ulcers in animals. *In: Gastroduodenal Ulcers. Butterworth & Company Ltd., London, Chapter 21*	
PTX0766	Dajani Docs Considered				1982	Mucosal enzyme activities, with special reference to enzymes implicated in bicarbonate secretion, in the duodenum of rats with cysteamine-induced ulcers. *Clin Sci 64: 341*	
PTX0767	Dajani Docs Considered				1982	Drug-induced duodenal ulcers. Structure activity correlation and pathogenesis. *In: Drugs and Peptic Ulcer. Volume II. Edited by Peiffer CJ, CRC Press, Boca Ratton, Florida*	
PTX0768	Dajani Docs Considered				1964	Experimental Histamine ulceration. *In: Pathophysiology of Peptic Ulcer. Edited by SC Skoryna, J.B. Lippincott Co., Philadelphia*	
PTX0769	Dajani Docs Considered				2001	Pharmacokinetics. The dynamics of drug absorption, distribution and elimination. *In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. Edited by Hardman JG, Limbird LE, Gilman AG. Tenth Edition. McGraw Hill, New York, pp 3-30*	
PTX0770	Dajani Docs Considered				1964	*Antipeptic and anti-ulcerogenic properties of synthetic sulfated polysaccharide (SN-263). Gastroenterology 47: 409-414*	
PTX0771	Dajani Docs Considered				1968	*Gastro 55:125-134*	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 15 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0772	Dajani Docs Considered				1966	*A J Digestive Dis 11:231241*	
PTX0773	Dajani Docs Considered				1998	Wilson and Gisvold's Textbook of organic medicinal and pharmaceutical chemistry Chapter 2 (Block) pp. 3-42	
PTX0774	Dajani Docs Considered				1967	*Gastro 52:959-965*	
PTX0775	Dajani Docs Considered				1955	*J Am Chem 77:4181-4182*	
PTX0776	Dajani Docs Considered				1967	*Am J Surg 113:183-187*	
PTX0777	Dajani Docs Considered				1989	*Drugs 37(5):628-668*	
PTX0778	Dajani Docs Considered				1955	*J Am Chem Soc 77:4438-4439*	
PTX0779	Dajani Docs Considered				1976	*Gastro 70:359-370*	
PTX0780	Dajani Docs Considered				1973	*Nature (London) 244:458-459*	
PTX0781	Dajani Docs Considered				1955	*J Am Chem Soc 77:3166-3167*	
PTX0782	Dajani Exhibit O				2000	Novel therapeutic approaches to gastric and duodenal ulcers: an update	
PTX0783	Dajani Exhibit O				1956	Textbook of Organic Medicinal and Pharmaceutical Chemistry pp. 59-61	
PTX0784	Dajani Exhibit O				1995	Gen Pharma 26:1027-1032 (1995)	
PTX0785	Dajani Exhibit O				1981	*"Indomethacin Produced Gastric Antral ulcers in the Refed Rat" Gastroenterology*, vol. 81, pp. 719-25 (1981)	
PTX0786	Dajani Exhibit O				1989	*J. Pharmacology Experimental Therapeutics*, vol. 248 no. 2, pp. 806-815 (1989)	
PTX0787	Dajani Expert Report O				2001	Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses, *Expert Opin. Pharmacother. 2(10):1663-1664*	
PTX0788	Dajani Expert Report O				1999	*Relative efficacies of gastric proton pump inhibitors: Their clinical and pharmacological basis. Pharmacology 59: 57-77*	Dajani Expert Report O
PTX0789	Dajani Expert Report O				2005	*Mechanism of action of leptin in preventing gastric ulcer. World J Gastro 11(27): 4154-4160*	
PTX0790	Dajani Expert Report O				2000	*Comparison of five antisecretory agents acting via gastric H+/K+ ATPase. J Physiol (Paris) 94: 19-23*	
PTX0791	Dajani Expert Report O				1997	*Proton-pump inhibitorsd: three of a kind. Lancet 349: 1637-1638*	
PTX0792	Dajani Expert Report O				2005	*What is potent acid inhibition, and how can it be achieved? Drugs 65 (suppl 1): 13-23*	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 16 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0793	Dajani Expert Report O				2002	*Comparative study on the activity of lansoprazole, omeprazole, and PD-136450 on acidifid ethanol-and indomethacin-induced gastric lesions in the rats. Clinical and Experimental Pharmacol and Physiol 29: 173-180*	
PTX0794	Dajani Expert Report O				1977	*Synthesis and gastric antisecretory properties of 15-deoxy, 16-hydroxy E-prostaglandin analogs. J Med Chem 20:1152-1159*	
PTX0795	Dajani Expert Report O				1979	*Effects of prostaglandin El derivative, SC-29333, and aspirin on gastric ionic fluxes and potential difference in dogs. J Pharmacol Exp Therap 210:283-288*	
PTX0796	Dajani Expert Report O				1986	*Is peptic ulcer a prostaglandin deficiency disease? An editorial. Human Pathology 17:106-107*	
PTX0797	Dajani Expert Report O				1975	*Comparative gastric antisecretory and antiulcer effects of prostaglandin El and its methyl ester in animals. Prostaglandins 10(2): 205-215*	
PTX0798	Dajani Expert Report O				1995	*Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: Role of mucosal protective and gastric anti-secretory drugs. Digestive Diseases 12. (suppl 1): 46-61*	
PTX0799	Dajani Expert Report O				1974	*Prevention and treatment of gastric and duodenal ulcers induced by nonsteroidal anti-inflammatory drugs. IN: NSAIDs-Mechanisms and clinical use. Eds. Lewis AJ, Furst D, Marcel Dekker, New York, pp 159-170*	
PTX0800	Dajani Expert Report O				1969	*The production of acute gastric ulceration by indomethacin in rat. Scand J Gastroenterol 4: 265-267*	
PTX0801	Dajani Expert Report O				1975	*Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochemical Pharmacolo 25: 1749-1754*	
PTX0802	Dajani Expert Report O				1974	Fluorinated compounds of medicinal interest *Chemtech pp. 752-757 (1974)*	
PTX0803	Dajani Expert Report O				2000	*The proton-pump inhibitors: Similarities and differences. Clin Ther 22: 266-280*	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 17 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0804	Dajani Expert Report O				1971	*The effects of antiulcer agents on indomethacin-induced gastric ulceration in the rats. Arch Int Pharmacodyn Therap 192: 370-377*	
PTX0805	Dajani Expert Report O				1970	Exertion ulcer in the rat. *Am J Dig Dis 15(5): 497-507*	
PTX0806	Dajani Expert Report O				1974	*Inhibition of indomethacin induced gastric ulceration in rat by perorally-administered synthetic and natural prostaglandin analogues. Prostaglandins 7(1): 1-10*	
PTX0807	Dajani Expert Report O				1992	*Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44(1): 9-35*	
PTX0808	Dajani Expert Report O				1979	*Cytoprotection by Prostaglandins. Gastroenterology 77: 761-767*	
PTX0809	Dajani Expert Report O				2003	*Clinical pharmacology of proton pump inhibitors. Drugs 63(24): 2739-2754*	
PTX0810	Dajani Expert Report O				1945	*A simple method for the uniform production of gastric ulceration in the rat. Gastroenterology 5: 43-6*	
PTX0811	Dajani Expert Report O				1986	Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. *Dig Dis Sci 31 (10): 1114-1122*	
PTX0812	Dajani Expert Report O				1999	Effects of pantaprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole. *J Gastroenterology Hepatology 14: 251-257*	
PTX0813	Dajani Expert Report O				2000	Evaluation of omeprazole, lansoprazole, pantoprazole, and -rabeprazole in the treatment of acid-related diseases. *J Am Pharm Assoc 40: 52-62*	
PTX0814	Dajani Expert Report O				1997	*Lansoprazole: A comprehensive review. Pharmacotherapy 17(2): 308-326*	
PTX0815	Dajani Expert Report O				1997	Lansoprazole: A Comprehensive Review, *Pharmacotherapy 17(2) 308-326*	
PTX0816	Fennerty Docs Considered				2007	Gastrointestinal Medications, *Psychosomatics 48:1, Jan-Feb 2007*	
PTX0817	Lenz Docs Considered				1989	*Acta Chem Scand 43:536-548* (LA Survey)	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 18 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0818	Lenz Docs Considered				1989	*Acta Chem Scand 43:549-568* (Kinetics of the reaction 2-mercapoethanol)	
PTX0819	Lenz Docs Considered				1989	*Acta Chem Scand 43:569-576* (protolytic behaviour)	
PTX0820	Lenz Docs Considered				1989	*Acta Chem Scand 43:587-594* (reaction of N-Alkylated derivates)	
PTX0821	Lenz Docs Considered				1989	*Acta Chem Scand 43:595-611* (reaction of omeprazole in the absence of 2-mercaptoethanol)	
PTX0822	Lenz Docs Considered				1958	*J AM Chem Soc 80:148-156*	
PTX0823	Lenz Docs Considered				1965	*J Org Chem 30:3346-3550*	
PTX0824	Lenz Docs Considered				2003	*Gastro Nursing 26:182-190*	
PTX0825	Lenz Docs Considered				1953	*Chem Rev 53:191-261*	
PTX0826	Lenz Docs Considered				1983	*Arznein-Forsch Drug Res. 33(II), Nr. 12, 1685-1686*	
PTX0827	Lenz Docs Considered				1964	*Journal of Organic Chemistry, Vol. 29, No. 2, 476-482*	
PTX0828	Lenz Docs Considered				1985	*Biochemical and Biophysical Research Communications, Vol. 128, No. 1, 477-484*	
PTX0829	Lenz Docs Considered				1989	*Acta Chemica Scand. 43:577-586*	
PTX0830	Lenz Docs Considered				1975	Correlation between Acidities of Carboxylic Acids and Core Ionization Potentials. J. Amer. Chem. Soc. 97:1265-1266	
PTX0831	Lenz Docs Considered				1967	Infrared Spectra and Structure of Tri- and Tetraalkylammonium Salts with Trihaloacetates and with Uranyl Trihaloacetates. Otd. Obshch. Tekh. Khim. 68-72	
PTX0832	Meyer Docs Considered				1993	Scanning and Transmission Electron Microscopy: An Introduction	
PTX0833	Meyer Docs Considered				2003	Scanning Electron Microscopy andX-Ray Microanalysis	
PTX0834	Meyer Docs Considered				1986	Infrared and Spectra of Inorganic and Coordination Compounds	
PTX0835	Meyer Docs Considered				1998	Principles of Instrumental Analysis, 5th Edition	
PTX0836	Meyer Docs Considered					www.renishaw.com	
PTX0837	Meyer Docs Considered					www.ich.org	
PTX0838	Meyer Docs Considered					www.edax.com	
PTX0839	Meyer Docs Considered				2000	Raman Spectroscopy for Chemical Analysis	
PTX0840	Solny Doc Considered				2006	*Aliment Pharmacol Ther Symp Ser 2, 327-339*	
PTX0841	Solny Doc Considered				2001	*Clinical Therapeutics, Vol. 23, No. 7, 998-1017*	

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 19 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0842	Solny Doc Considered				2000	*Journ Clinical Outcomes Management, Vol. 7, No. 11, 29-34*	
PTX0843	Solny Doc Considered				2005	*Evidence-Based Gastroenterology, Vol. 6, No. 4, 104-105*	
PTX0844	Solny Doc Considered				2005	*American Journal of Gastroenterology; 100: 190-200*	
PTX0845	Solny Doc Considered				2001	*Evidenced-Based Gastroenterology, Vol. 2, No. 4, 160-168*	
PTX0846	Solny Doc Considered				2004	*Evidenced-Based Gastroenterology, Vol. 5, No. 1, 2-3*	
PTX0847	Solny Doc Considered				2002	*Aliment Pharmacol Ther 2002; 16: 35-39*	
PTX0848	Solny Doc Considered				2006	*Aliment Pharmacol Ther symp ser 2, 340-350*	
PTX0849	Solny Doc Considered				2001	*Best Practice & Research Clinical Gastroenterology, Vol. 15, No. 3, pp. 371-384*	
PTX0850	Solny Doc Considered				2002	*Current Gastroenterology Reports 4:459-462*	
PTX0851	Solny Doc Considered				2004	*Drug Class Review on Proton Pump Inhibitors - Final Report*	
PTX0852	Solny Doc Considered				2003	*American Journal of Gastroenterology, Vol. 98, No. 12, 26162620*	
PTX0853	Solny Doc Considered				2000	*Current Gastroenterology Reports, 4:482-493*	
PTX0854	Solny Doc Considered				2002	*Aliment Pharmacol Ther 2002; 16 *Suppl. 4): 73-78*	
PTX0855	Solny Doc Considered				2002	Commentary, Lansoprazole Provided More Effective and Faster Relieffor Heartburn Than Did Omeprazole in Erosive Esophagitis, 136(3) ACP J. Club 95	
PTX0856	Solny Doc Considered					TAP 0273338	TAP 0273338
PTX0857	Vandaele Docs Considered				1999	"Do Pharmaceutical Sales Respond to Scientific Evidence?" Program on the Pharmaceutical Industry, Massachusetts Institute of Technology Working Paper WP #51-99, April 1999	
PTX0858	Vandaele Docs Considered					Pharmaceutical Product Ranking.xls	
PTX0859	Vandaele Docs Considered					Prevacid Xponent Specialty Tool xis	
PTX0860	Vandaele Docs Considered					Top 10 Products and Market Trends for Sandi_050907.xIs	
PTX0861	Whittle Docs Considered				1999	Aliment, Pharmacol. Ther., vol. 13, pp. 1553-1562	WHITTLE 000607-000616
PTX0862	Whittle Docs Considered				1991	*Japan. J. Pharmacol.*, vol. 55, pp. 437-451	WHITTLE 000642-000646; 000657-000661
PTX0863	Whittle Docs Considered				1991	*Jpn. Pharma. Ther.*, vol. 19, no. 2, pp. 89(477)-98(486)	WHITTLE 000647-000656; 000662-000672

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 20 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0864	Whittle Docs Considered				1992	*Jpn. Pharma. Ther.*, vol. 20, no. 11, pp. 65(4335)-74(4344)	WHITTLE 000630-000641; 000673-000684
PTX0865	Whittle Docs Considered				1997	*Jpn. Pharma. Ther.*, vol. 25, no. 10, pp. 59(2445)-69(2455)	WHITTLE 000685-000697; 000744-000756
PTX0866	Whittle Docs Considered				1988	*Gastroenterology*, vol. 95, pp. 932-944	WHITTLE000711-000723
PTX0867	Whittle Docs Considered				1990	*Chem. Pharm. Bull.*, vol. 38(10), pp. 2853-2858	WHITTLE 000724-000730
PTX0868	Whittle Docs Considered				2000	*Digestive Diseases and Sciences*, vol. 45, no. 7, pp. 1359-1365	WHITTLE 000757-000763
PTX0869	Whittle Docs Considered				2000	*Bailliere's Clinical Gastroenterology*, vol. 14, no. 1, pp. 75-96	WHITTLE000764-000785
PTX0870	Whittle Docs Considered				1978	*Int. J. Biometeor*, vol. 22, no. 3, pp. 190-196	WHITTLE 000786-000792
PTX0871	Whittle Docs Considered				1983	*European Journal of Pharmacology*, vol. 89, pp. 243-250	WHITTLE 000793-000800
PTX0872	Whittle Docs Considered				1991	*Japan J. Pharmacol.*, vol. 55, pp. 425-436	WHITTLE 000808-000819; 000820-000831
PTX0873	Whittle Docs Considered				2005	*Chem. Res. Toxicol.*, vol. 18, pp. 123-128	WHITTLE 000851-000856
PTX0874	Whittle Docs Considered				1983	*Gastroenterology*, vol. 83, pp. 210-215	WHITTLE 000878-000883
PTX0875	Whittle Docs Considered				1983	*Gastroenterology*, vol. 84, pp. 483-489	WHITTLE 000884-000890
PTX0876	Whittle Docs Considered				2004	*Fundamental & Clinical Pharmacology*, vol. 18, pp. 23-3	WHITTLE 000908-000916
PTX0877	Whittle Docs Considered				1991	*Journal of Biopharmaceutical Sciences*, vol. 2(4), pp. 319-328	WHITTLE 000948-000958
PTX0878	Whittle Docs Considered				1991	*J. Physiol.*, vol. 93, pp. 437-442	WHITTLE 000970-000975
PTX0879	Whittle Docs Considered				1997	*Abstract: A Novel and Simple Method for Inducing Gastric Antral Ulcer in Refed Rats by Combined Treatment with Hydrochloric Acid and Indomethacin*	WHITTLE 000969
PTX0880	Whittle Docs Considered				1977	*IRCS Medical Science*, vol. 5, p. 501	WHITTLE 000976
PTX0881	Whittle Docs Considered				1988	*Digestion*, vol. 41, pp. 78-82	WHITTLE 000990-000994
PTX0882	Whittle Docs Considered				1985	*Gastroenterology*, vol. 89, pp. 86-91	WHITTLE 000995-001000
PTX0883	Whittle Docs Considered				1991	*Life Sciences*, vol. 48, pp. 2035-2042	WHITTLE 001001-001008
PTX0884	Whittle Docs Considered				1993	*Can. J. Physiol. Pharmacol.*, vol. 71, pp. 447-452	WHITTLE 001009-001014
PTX0885	Whittle Docs Considered					U.S. Patent 4,045,563	WHITTLE 000348-000361
PTX0886	Whittle Docs Considered					U.S. Patent 4,255,431	WHITTLE 000362-000375
PTX0887	Whittle Docs Considered					U.S. Patent 4,359,465	WHITTLE 000376-000389
PTX0888	Whittle Docs Considered					U.S. Patent4,575,554	WHITTLE 002001-002012

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 21 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0889	Whittle Docs Considered					ORGANIX Inc. letter, November 29, 2006	WHITTLE 001745-001818
PTX0890	Whittle Docs Considered					PSL 000001-000673	WHITTLE 001072-001744
PTX0891	Lipinski Docs Considered				1975	J. Am. Chem. Soc., vol. 97:8, pp. 2198-2205	LIPINSKI 000230-000237
PTX0892	Lipinski Docs Considered				1984	Br. J. Pharmac., vol. 82, pp. 651-657	LIPINSKI 000238-000244
PTX0893	Lipinski Docs Considered				1987	Pharmacology, vol. 34, pp. 269-278	LIPINSKI 000245-000254
PTX0894	Lipinski Docs Considered				1981	J. Med. Chem., vol. 24, pp. 927-932	LIPINSKI 000255-000260
PTX0895	Lipinski Docs Considered				1960	Ionization Constants of Substituted Pyridines and Quinolines, vol. 82, pp. 4871-4877	LIPINSKI 000261-000267
PTX0896	Lipinski Docs Considered					Pharmacology and Toxicology of Omeprazole-With Special Reference to the Effects on the Gastric Mucosa, pp. 31-38	LIPINSKI 000268-000275
PTX0897	Lipinski Docs Considered				1965	Structure and Basicity, Part III, pp. 2804-2811	LIPINSKI 000288-000295
PTX0898	Lipinski Docs Considered				1982	American Physiological Society, pp. G505-G510	LIPINSKI 000296-000301
PTX0899	Lipinski Docs Considered				1980	Elsavier/North-Holland Biomedical Press, pp. 193-202	LIPINSKI 000302-000311
PTX0900	Lipinski Docs Considered				1981	Nature, vol. 290, pp. 159-161	LIPINSKI 000312-000314
PTX0901	Lipinski Docs Considered				1982	Biomedicinal Aspects of Fluorine Chemistry	LIPINSKI 000315-000442
PTX0902	Lipinski Docs Considered				2006	Analogue-based Drug Discovery	LIPINSKI 000443-000549
PTX0903	Lipinski Docs Considered				1984	Gastroenterology, vol. 87, pp. 1064-1071	LIPINSKI 000550-000557
PTX0904	Lipinski Docs Considered				1984	Scand. J. Gastroenterol., vol. 19 (suppl. 101), pp. 21-26	LIPINSKI 000558-000563
PTX0905	Lipinski Docs Considered				1986	Journal of Medicinal Chemistry, vol. 29, no. 8, pp. 1327-1329 (1986) ()	LIPINSKI 000285-000287
PTX0906	Lipinski Docs Considered				1989	J. of Pharmacology and Experimental Therapeutics, vol. 248, no. 2, pp. 806-815	LIPINSKI 000574-000583
PTX0907	Lipinski Docs Considered				1987	J. Org. Chem., vol. 52, pp. 4582-4592	LIPINSKI 000945-000955
PTX0908	Lipinski Docs Considered				1984	Agents and Actions, vol. 14, pp, 319-324	LIPINSKI 000584-000589
PTX0909	Lipinski Docs Considered				1987	J. Org. Chem., vol. 52, pp. 4573-4581	LIPINSKI 000590-000598
PTX0910	Lipinski Docs Considered				1977	Acta Phrmacologica et Toxicologica, vol. 41, supplement IV, p. 77	LIPINSKI 000599-000600
PTX0911	Lipinski Docs Considered				1984	Biochimica et Biophysica Acta, vol. 778, pp. 549-558	LIPINSKI 000601-000610
PTX0912	Lipinski Docs Considered				1983	Biochimica et Biophysica Acta, vol. 728, pp. 31-38	LIPINSKI 000611-000618
PTX0913	Lipinski Docs Considered				1985	The Journal of Biological Chemistry, vol. 260, no. 25, pp. 13681-13684	LIPINSKI 000619-000622
PTX0914	Lipinski Docs Considered					EP 0174726(B1)	LIPINSKI 001711-001723
PTX0915	Lipinski Docs Considered					EP 0045200 (B1)	LIPINSKI 001655-001665

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 22 of 118

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0916	Lipinski Docs Considered					EP 0005129 (B1)	LIPINSKI 001640-001654
PTX0917	Lipinski Docs Considered					EP 0074341	LIPINSKI 001666-001710
PTX0918	Lipinski Docs Considered					EP GB2134523A	LIPINSKI 001724-001767
PTX0919	Lipinski Docs Considered					U.S. Patent 4,045,563	LIPINSKI 002624-002637
PTX0920	Lipinski Docs Considered					U.S. Patent 4,359,465	LIPINSKI 002638-002651
PTX0921	Lipinski Docs Considered					U.S. Patent 4,472,409	LIPINSKI 002652-002661
PTX0922	Lipinski Docs Considered					U.S. Patent 4,575,554	LIPINSKI 002425-002436
PTX0923	Lipinski Docs Considered					U.S. Patent 5,045,552	LIPINSKI 002437-002481
PTX0924	Bugay document production					Bugay CD	BUGAY 000196
PTX0925	Bugay document production					Bugay CD	BUGAY 000197
PTX0926	Bugay Expert Report 45					Raw data CD	BUGAY 0132
PTX0927	Bugay Supplemental Expert Report 56					CD with EDX results	BUGAY 0195
PTX0928	Hirsch document production					Hirsch document production of Excel files	
PTX0929	Kaunitz Docs Considered					Documents having Bates Nos. PSL 1-561	PSL 000001-000561
PTX0930					1981	Indomethacin Produced Gastric Antral ulcers in the Refed Rat *Gastroenterology*, vol. 81, pp. 719-25 (1981)	
PTX0931					1995	Biomedical Research Manual Vol. VI Disease-model Animals Chapter 2: Experimentally-induced and Naturally Occurring Models Pages 124-125	
PTX0932						TAKEDA 048057-048070	
PTX0933						TAKEDA 047615	TAKEDA 048057-048070
PTX0934						TAKEDA 047596	TAKEDA 047615
PTX0935						TAKEDA 047583	TAKEDA 047596
PTX0936						TAKEDA 047572	TAKEDA 047583
PTX0937						TAKEDA 047565	TAKEDA 047572
							TAKEDA 047565

Case 1:06-cv-00033-SLR Document 146-3 Filed 10/08/2007 Page 23 of 118

EXHIBIT 6

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

TAKEDA PHARMACEUTICAL COMPANY LTD. AND TAP PHARMACEUTICAL PRODUCTS INC.
V. TEVA PHARMACEUTICALS USA, INC. AND TEVA PHARMACEUTICAL INDUSTRIES LTD.

CIVIL ACTION NO. 1:06-CV-0033-SLR

TEVA PHARMACEUTICALS USA, INC. AND
TEVA PHARMACEUTICAL INDUSTRIES LTD.

TRIAL EXHIBIT LIST

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX1				U.S. Patent 4,628,098	12/09/86	TVL 010937-10943
DTX2				U.S. Patent 4,628,098 File History	12/09/86	TVL 010937-10943
DTX3				U.S. Patent 5,045,321	09/03/91	TVL 010962-010972
DTX4				U.S. Patent 5,045,321 File History	02/15/87	TAKEDA 739426-739858
DTX5				U.S. Patent 4,255,431	03/10/81	TVL 011020-11029
DTX6				U.S. Patent 4,255,431 File History	04/05/79	TAKEDA 389629-389829
DTX7				U.S. Patent 4,472,409	09/18/84	TVL 011030-11039
DTX8				U.S. Patent 4,472,409 File History	06/21/84	TVL 069908-70042
DTX9				U.S. Patent 4,555,518	11/26/85	TVL 059822-59837
DTX10				U.S. Patent 4,555,518 File History	05/01/84	TVL 070043-70192
DTX11				U.S. Patent 4,045,563	08/30/77	TVL 010912-10925
DTX12				U.S. Patent 4,045,564	08/30/77	TVL 064006-64012
DTX13				Publication Entitled *"Pump Blockers & Ulcer Disease,"* New England Journal of Medicine, by Sachs	03/22/84	TVL 063219-63221
DTX14				NDA No. 20-406 – CD	00/00/00	TAP 000664-194332
DTX15				ANDA #77-255 – CD	00/00/00	TVL 000001-7850
DTX16				U.S. Patent 4,686,230	08/11/87	TVL 011082-11106
DTX17				U.S. Patent 4,686,230 File History	03/00/89	TVL 070193-70335
DTX18				Japanese Patent Application No. 19715/85	01/31/85	TAKEDA 681581-681598
DTX19				U.S. Patent 4,666,919	05/19/87	TVL 011076-11081
DTX20				U.S. Patent 5,026,560	06/25/91	TVL 010956-10961

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX21				U.S. Patent 5,026,560 File History	01/14/88	TVL 008854-9046
DTX22				U.S. Patent 5,093,132	03/03/92	TVL 010973-10986
DTX23				U.S. Patent 5,093,132 File History	08/31/90	TVL 009449-9587
DTX24				U.S. Patent 5,433,959	07/18/95	TVL 010987- 11002
DTX25				U.S. Patent 5,433,959 File History	07/18/95	TVL 009588-9787
DTX26				First Expert Report of W. Chambliss	06/26/07	
DTX27				Data & Information Considered in Support of First Chambliss Report	06/26/07	CHAMBLISS 06/26/07 REP. EX. B
DTX28				Second Expert Report of W. Chambliss	08/08/07	
DTX29				Rebuttal Expert Report of W. Chambliss	08/13/07	CHAMBLISS DEP. EX. 7
DTX30				Curriculum Vitae of W. Chambliss	00/00/00	
DTX31				Data & Information Considered in Support of Second Chambliss Report	08/08/07	CHAMBLISS 08/08/07 REP. EX. B
DTX32				Chart: Particle Size Conversion	08/08/07	CHAMBLISS DEP. EX. 11
DTX33				Publication Entitled *"Omeprazole, A Study of Its Inhibition of Gastric pH & Oral Pharmacokinetics after Morning or Evening Dosage,"* by Prichard, et al.	00/00/85	TVL 065992-65997
DTX34				Publication Entitled *"Kinetic Analysis of Penicillin Degradation of Acidic Media,"* Journal of Pharmaceutical Sciences by Blaha, et al.	08/00/76	TVL 065978-65984
DTX35				Publication Entitled *"Digoxin Degradation in Acidic Dissolution Medium,"* by Sonobe	04/04/80	TVL 063845-63848
DTX36				Publication Entitled *"The Forgotten Dosage Form: Enteric-Coated Tablets,"* Pharmaceutical Technology, by Chambliss	09/00/83	TVL 065972-65977
DTX37				Publication Entitled *"Evidence for Acid-induced Transformation of Omeprazole into an Active Inhibitor by (H+ + K+)-ATPase Within the Parietal Cell,"* by Wallmark, et al.	08/15/84	TVL 063980-63989
DTX38				Publication Entitled *"Hydrogen Peroxide Solution (3 per cent),"* British Pharmecopeia	12/01/98	CHAMBLISS DEP. EX. 28
DTX39				Composite with Amidon Expert Report & CV, Westlaw Document - Tabeta, et al., Publication Entitled *"Chemical Stability of Pharmaceuticals,"* by Connors, et al., & Handbook of Pharmaceutical Excipients from Chambliss	00/00/00	CHAMBLISS DEP. EX. 29
DTX40				U.S. Patent Application No. 07/014,303 – Declaration Under Rule 132	02/13/87	TAKEDA 739677-739680

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX41				Publication Entitled *"The Theory & Practice of Industrial Pharmacy,"3rd Edition* by Lachman, Lieberman, & Kanig	00/00/86	TVL 069283-69285
DTX42				Publication Entitled "*Development of an Oral Formulation of Omeprazole,"* Gastroenterology, by Pilbrant & Cederberg	00/00/00	TVL 059548-59557
DTX43				ANDA #77-255 – Section VII – Components & Composition Statements	07/00/04	TVL 006613-6822
DTX44				Publication Entitled *"The U.S. Pharmacopoeia, 21st Revision, The National Formulary"* 16th Edition	01/01/85	TVL 059558-59564
DTX45				Publication Entitled "*Remington's Pharmaceutical Science: Powders,"* 15th Edition	00/00/75	TVL 063869-63871
DTX45.1				Publication Entitled "*Remington's Pharmaceutical Science: Stability of Pharmaceutical Products,"* 15th Edition	00/00/75	TVL 063886-63888
DTX46				Publication Entitled *"Pharmaceutical Pelletization Technology,"* edited by Ghebre-Sellassie	00/00/89	TVL 063839-63841
DTX 46.1				Publication Entitled *"Pellets: A General Overview,"* edited by Ghebre-Sellassie	00/00/89	TVL 069308-69310
DTX47				Data & Information Considered by W. Chambliss	00/00/00	CHAMBLISS REBUTTAL RPT. EX. A
DTX48				Prior Deposition or Trial Testimony in Last Five Years of Chambliss	00/00/00	CHAMBLISS EXPERT RPT. EX. C
DTX49				Publication Entitled *"The Theory & Practice of Industrial Pharmacy: Kinetic Principles & Stability Testing,"* 2nd Edition, by Lachman, Lieberman, & Kanig	00/00/78	TVL 065988-65991
DTX49.1				Publication Entitled *"The Theory & Practice of Industrial Pharmac: Mixing,"* 2nd Edition, by Lachman, Lieberman, & Kanig	00/00/78	TVL 069297-69300
DTX50				Publication Entitled *"Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists"* by Connors, Amidon & Kennon	00/00/79	TVL 063880-63885
DTX51				Excerpt from '321 Patent File History – Amendment	03/10/81	TAKEDA 739684
DTX52				Publication Entitled *"Handbook of Pharmaceutical Excipients,"* 5th Edition, by Rowe, et al.	00/00/00	TVL 069301-69307
DTX53				U.S. Patent 2,991,226	07/04/61	TVL 069286-69291
DTX54				Publication Entitled *"Modern Pharmaceutics,"* 3rd Edition, by Banker & Rhodes	00/00/96	TVL 069292-69296
DTX55				Publication Entitled *"The United States. Pharmacopoeia, 21st Revision"*	01/01/85	TVL 059558-59564

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX56				ANDA #77-255 - Section XI.2 – Manufacturing & Processing Instructions Commercial Batch Records	07/15/04	TVL 006849-6907
DTX57				Expert Report of A. Hirt	08/06/07	KITAO DEP. EX. 1
DTX58				Curriculum Vitae of A. Hirt	00/00/00	HIRT EXPERT RPT. EX. B
DTX59				Data & Documentation in Support of Hirt Report, with Referenced CD	00/00/00	HIRT EXPERT RPT. EX. C
DTX60				Prior Deposition or Trial Testimony in Last Five Years of A. Hirt	00/00/00	HIRT EXPERT RPT. EX. D
DTX61				E-mail from L. Fritts to D. Kim & J. Blake	08/27/07	HIRT DEP. EX. 3
DTX62				Letter from D. Cole to A. Hirt	07/12/07	HIRT 0071-74
DTX63				Publication Entitled *"Report MRL3862: Analytical Study of Lansoprazole Granules using Diamond Knife Microtomy, Time-of Flight Secondary Ion Mass Spectroscopy, Laser Raman Spectroscopy, Scanning Electron Microscopy & Energy-Dispersive X-ray Spectroscopy"*	08/06/07	HIRT 0001-47
DTX64				Raman Spectroscopy: Sample Analysis Form	00/00/00	HIRT 0048-70
DTX65				Expert Report of G. Meyer	08/08/07	MEYER DEP. EX. 1
DTX66				Curriculum Vitae of G. Meyer	00/00/00	MEYER EXPERT RPT. EX. B
DTX67				Data & Information Considered by G. Meyer	00/00/00	MEYER EXPERT RPT. EX. C
DTX68				Prior Deposition or Trial Testimony in Last Five Years of Meyer	00/00/00	MEYER EXPERT RPT. EX. D
DTX69				Publication Entitled *"Validation of Analytical Procedures: Text & Methodology Q2(R1)"*	11/00/05	MEYER EXPERT RPT. EX. E
DTX70				Publication Entitled *"Infrared & Raman Characteristic Group Frequencies,"* by Socrates	00/00/01	MEYER EXPERT RPT. EX. F
DTX71				Expert Report of G. Lenz	06/27/07	LENZ DEP. EX. 4
DTX72				Second Expert Report of G. Lenz	08/13/07	LENZ DEP. EX. 17
DTX73				Curriculum Vitae of G. Lenz	00/00/00	LENZ 1ST EXPERT RPT. EX. A
DTX74				List of Articles Reviewed or Relied upon by G. Lenz	00/00/00	LENZ 1ST EXPERT RPT. EX. B
DTX75				Publication Entitled *"Dissociation Constants of Organic Bases in Aqueous Solution,"* by Perrin	00/00/65	TVL 065643-65712

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX76				Publication Entitled *"Histamine & 5-Hydroxytryptamine (Serotonin) & Their Antagonists,"* The Pharmacological Basis of Therapeutics, 6th Edition, by Douglas	00/00/80	TVL 063935-63943
DTX77				Publication Entitled *"Structure & Basicity. Part III: The Basicity of Homogeneously Substituted Cyclotriphospazatrienes & Cyclotetraphosphazatetraenes,"* by Feakins, et al.	03/00/65	TVL 059746-59755
DTX78				Publication Entitled *"Substituted Benzimidazoles Inhibit Gastric Acid Secretion by Blocking (H^++K^+) ATPase,"* Nature, by Fellenius, et al.	03/12/81	TAKEDA 362159-362161
DTX79				Publication Entitled *"Atropine, Scopolamine, & Related Antimuscarinic Drugs,"* The Pharmacological Basis of Therapeutics, 6th Edition, by Weiner	00/00/80	TVL 063915-63934
DTX80				Publication Entitled *"Steric Effects in Displacement Reactions III: The Base Strengths of Pyridine, 2,6-Lutidine & the Monoalkylpyridines"*	04/05/55	TVL 063303-63306
DTX81				Publication Entitled *"Thermodynamics of Protonation of Substituted Pyridines in Aqueous Solutions"*	00/00/00	TVL 063307-63311
DTX82				Publication Entitled *"Synthesis of 2-[(4-Fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidaxoles as Antiulcer Agents,"* by Kubo, Oda, Kaneko, Satoh, & Nohara	10/00/90	TAKEDA 015682-15687
DTX83				Certified Translation of Central Research Division Monthly Report, June 1984	06/01/84	TAKEDA 040929-935
DTX84				Publication Entitled *"Structure & Reactivity in the Pyridine Series. Part I: Acid Dissociation Constants of Pyridinium Ions,"* by Hoshini	00/00/64	TVL 065625-65630
DTX85				Publication Entitled *"Gastric Antacids & Digestants,"* by Harvey	00/00/80	TVL 063899-63914
DTX86				Certified Translation of Central Research Division Monthly Report, July 1984	07/01/84	TAKEDA 040936-942
DTX87				Publication Entitled *"Consultant Comment,"* New Ethicals, by Scobia	02/00/91	TAKEDA 683409-683412
DTX88				Publication Entitled *"Effects of a Proton Pump Inhibitor, Omeprazole, on Gastric Secretion & Gastric & Duodenal Ulcers or Erosions in Rats"*	01/94	TVL 069356-69364
DTX89				Glaxo Wellcome: Knowledge Acquisition & Learning	00/00/05	TVL 069353-69355
DTX90				Publication Entitled *"The Pharmacology of Antiulcer Drugs"*	10/00/89	TVL 069365-69373

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX91				Data & Information Considered of Lenz	00/00/00	LENZ 2ND EXPERT RPT. EX. A
DTX92				Affidavit of Direct Testimony of Professor Hopfinger – Eisai v. Teva, Case No. 03-CV-9053	02/28/07	DAJANI DEP. EX. 3
DTX93				Publication Entitled *"Medicinal Chemical Properties of Successful Central Nervous System Drugs,"* by Pajouhesh & Lenz	00/00/00	LENZ DEP. EX. 11
DTX94				ChemSpider Beta Data: Search Results for Pantoprazole	00/00/00	LENZ DEP. EX. 12
DTX95				ChemSpider Beta Data: Search Results for Pantoprazole	00/00/00	LENZ DEP. EX. 13
DTX96				ChemSpider Beta Data: Search Results for Rabeprazole	00/00/00	LENZ DEP. EX. 14
DTX97				ChemSpider Beta Data: Search Results for Omeprazole	00/00/00	LENZ DEP. EX. 15
DTX98				Publication Entitled "*Patent & Trademark Copyright Laws Editied,"* June 2007 Edition, by Samuels	06/00/07	LENZ DEP. EX. 18
DTX99				U.S. Patent 4,500,708	02/19/85	LENZ DEP. EX. 2
DTX100				Publication Entitled *"Omeprazole: The First Proton Pump Inhibitor,"* by Lindberg	00/00/90	TAKEDA 360478-360531
DTX101				Publication Entitled *"A Survey of Hammett Substituent Constants & Resonance & Field Parameters,"* by Hansch	12/07/90	TVL 063319-63349
DTX102				Expert Report of E. Dajani	06/27/07	DAJANI DEP. EX. 20
DTX103				Curriculum Vitae of E. Dajani	00/00/00	DAJANI DEP. EX. 1
DTX104				References & Documents Reviewed & Relied upon by E. Dajani	00/00/00	DAJANI DEP. EX. 22
DTX105				Prior Deposition or Trial Testimony in Last Five Years	00/00/00	DAJANI EXPERT RPT. EX. C
DTX106				Publication Entitled *"1',1' -Dimethylheptyl*Δ*-8-tetrahydrocannabinol-11-oic Acid: A Novel, Orally Effective Cannabinoid with Analgesic & Anti-inflammatory Properties,"*	03/02/99	DAJANI DEP. EX. 10
DTX107				Publication Entitled "*Ulcer Disease: Investigation & Basis for Therapy – Chapter 22: Pharmaceutical Industry Perspectives on Human Investigation & Development of Anti-Ulcer Drugs,"* by Swabb & Szabo	00/00/91	DAJANI DEP. EX. 2
DTX108				Publication Entitled *Textbook of Organic Medicinal & Pharmaceutical Chemistry,"* by Wilson & Gisvold	00/00/00	TVL 069797-69828
DTX109				Publication Entitled *Textbook of Organic Medicinal & Pharmaceutical Chemistry,"* 3rd Edition, Wilson & Gisvold	00/00/00	TVL 069797-69828

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX110				Publication Entitled "*Drugs for Treatment of Peptic Ulcers,"* Journal of the Assoc. for Academic Minority Physicians, by Dajani & Trotman	07/00/92	DAJANI DEP. EX. 25
DTX111				Evaluation of Test Agent Inhibitors Against Indomethacin Induced Gastric Mucosal Irritation: Rats – Table 1 & 2	12/11/06	PSL 0462-465
DTX112				Transcript of H. Jacoby Deposition	08/14/07	DAJANI DEP. EX. 27
DTX113				First Declaration of G. Fuller – Eisai v. Teva, Case No. 03-CV-9053	03/01/07	DAJANI DEP. EX. 4
DTX114				European Patent Application No. 0 174 726	07/31/85	DAJANI DEP. EX. 5
DTX115				U.S. Patent 3,950,537	04/13/76	DAJANI DEP. EX. 7
DTX116				U.S. Patent 5,679,375	10/21/97	DAJANI DEP. EX. 8
DTX117				Publication Entitled *Synergistic Actions of Propantheline Bromide with Cimetidine and Thiopropazate Hydrochloride in the Prevention of Stress Ulcer Formation in Rats,"* by Dajani, Bianchi & Calhoun	05/07/79	DAJANI DEP. EX. 9
DTX118				U.S. Patent Application Publication No. US 2005/0020638 A1	01/27/05	DAJANI DEP. EX. 19
DTX119				European Patent EP-B-174,726 Appeal Brief	12/00/93	TAKEDA 358545
DTX120				Central Research Division AG-1749 (H++K+) – ATPase Inhibitor – Sept. 1986	09/00/86	TAKEDA 571236-571279
DTX121				PSL - O-5361 (Compound D) & Safety Data Sheet	11/29/06	DAJANI EXPERT RPT., EX. M
DTX122				Pre-Clinical & Clinical References Comparing Lansoprazole & Omeprazole	00/00/00	TAKEDA 642702-441658
DTX123				PSL - Comparison of Properties of Fluorinated & Non-fluorinated Drugs	00/00/00	PSL 0001-36
DTX124				Sigma-Aldrich: I8280 Indomethacin Meets USP Testing Specifications	00/00/00	TVL 066065-66066
DTX125				Curricula Vitae of G. Dong, Jacoby & Boulet	00/00/00	DAJANI EXPERT RPT. EX. L
DTX126				Publication Entitled *Fluorinated Compounds of Medicinal Interest"* by Filler	01/00/74	TVL 066324-66690
DTX 126.1				Publication Entitled *Fluorinated Compounds of Medicinal Interest"* by Filler		TVL 065998-66004
DTX127				Certified Translation of Central Research Division Monthly Report September 1984	09/01/84	TAKEDA 040951-957
DTX128				Expert Report of M. Solny	06/26/07	SOLNY DEP. EX. 3

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX129				Curriculum Vitae of M. Solny	09/27/05	SOLNY EXPERT RPT. EX. A
DTX130				Data & Information Considered by M. Solny	00/00/00	SOLNY DEP. EX. 2
DTX131				List of Court Testimony of M. Solny	00/00/00	SOLNY DEP. EX. 1
DTX132				Publication Entitled *"Lansoprazole vs. Omeprazole in Short-term Treatment of Reflux Oesophagitis,"* Scandinavian Journal of Gastroenterology	09/28/92	SOLNY DE P. EX. 10
DTX133				Publication Entitled *"Efficacy & Safety of Lansoprazole in the Treatment of Erosive Reflux Esophagitis,"* by Castell, et al.	05/13/96	FENNERTY 0306-314
DTX134				Publication Entitled *"Low-Dose lansoprazole provides Greater relief of heartburn & Epigastric pain than low-dose Omeprazole in patients with Acid-related dyspepsia,"* by Jones, et al.	10/24/98	FENNERTY 0357-363
DTX135				Publication Entitled *"Rapid Symptom Relief in Reflux Oesophagitis: A Comparison of Lansoprazole & Omeprazole,"* by Mee, et al.	05/28/96	FENNERTY 0412-418
DTX136				Publication Entitled *"Best Buy Drugs, Proton Pump Inhibitors,"* Consumer Reports	01/00/07	TVL 64522-64535
DTX137				Publication Entitled *"Gastroesophageal Reflux Disease,"* by Richter	00/00/07	SOLNY DEP. EX. 16
DTX138				Publication Entitled *"Lansoprazole vs. Omeprazole: Influence on Meal-Stimulated Gastric Acid Secretion,"* by Dammann, et al.	12/18/96	FENNERTY 0315-320
DTX139				Prilosec Product Description Sheet	00/00/00	SOLNY DEP. EX. 7
DTX140				Prevacid Product Description Sheet	00/00/00	SOLNY DEP. EX. 8
DTX141				Drug Class Review on Proton Pumo Inhibitors – Final Report	07/00/06	TVL 063419-63514
DTX142				Publication Entitled *"Lessons Learned from Intragastric pH Monitoring "*	00/00/01	TVL 063402-63408
DTX143				Publication Entitled *"Drugs to Treat Heartburn, Ulcers, & Stomach Acid Reflux: The Proton Pump Inhibitors"*	00/00/00	TVL 063992-64005 TVL 064522-64535
DTX144				Publication Entitled *"Lansoprazole Provided More & Faster Relief for Heartburn than did Omeprazole in Erosive Esophagitis"*	06/00/02	TVL 063990-63391
DTX145				Publication Entitled *"Management of Gastroesophageal Reflux Disease"*	11/00/03	TVL 063409-63418

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX146				Publication Entitled *"Treating Reflux Esophagitis: Symptom Relief in Patients with Reflux Esophagitis: Comparative Study of Omeprazole, Lansoprazole, & Rabeprazole,"* by Adachi, et al.	01/00/03	TVL 064021-64027
DTX147				Publication Entitled *"Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, & Stress-Related Erosive Syndrome,"* by Wolfe & Sachs	00/00/02	TVL 063350-63372
DTX148				Expert Report of W. Vandaele	08/13/07	VANDAELE DEP. EX. Ex. 1
DTX149				Curriculum Vitae of W. Vandaele	00/00/00	VANDAELE EXPERT RPT. EX. 1
DTX150				Data & Information Considered of W. Vandaele	08/13/07	VANDAELE EXPERT RPT. EX. 2
DTX151				Chart: Leading 20 Products by U.S. Sales, MAT 11/01 – 11/06	06/00/07	VANDAELE DEP. EX. 5
DTX152				Chart: TRx Trends by Specialty for Total Prevacid	00/00/00	VANDAELE DEP. EX. 6
DTX153				TOP 10 U.S. Products by Sale / Chart: PPI Market TRx Volume / Chart: PPI Market NRx Volume / PPI Market Sales Dollars	2001 – 2007	VANDAELE EXPERT RPT. EX. 32
DTX154				Publication Entitled *"Do Pharmaceutical Sales Respond to Scientific Evidence,"* Journal of Economics & Management Strategy, by Azoulay	00/00/02	VANDAELE DEP. EX. 8
DTX155				98 Stat. 1585, Public Law Section 98-417 – Drug Price Competition & Patent Term Restoration Act of 1984	09/24/84	TVL 064970-64991
DTX156				Brochure: Pharmaceutical Overview, Executive's Guide	00/00/04	TVL 065419-65423
DTX157				Brochure: Prescription Drug Trends: A Chartbook Update, by Kaiser Family Foundation	11/00/01	TVL 065287-65358
DTX158				Brochure: Santarus Presentation	09/27/06	TVL 064881-64905
DTX159				Chart: Comparison of Dosage Strengths/Formulations of Brand Name PPIs	1989-2006	VANDAELE EXPERT RPT. EX. 4
DTX160				Chart: Prevacid 1995-2006 Annual Sales Revenue	1995-2006	VANDAELE EXPERT RPT. EX. 3
DTX161				Chart: Prevacid 1995-2006 Historical Units/Gross Sales/Net Sales	1995-2006	VANDAELE EXPERT RPT. EX. 30
DTX162				Chart: Prevacid 2004-2006 Product Line P&L	2004-2006	VANDAELE EXPERT RPT. EX. 31

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX163				Chart: Prevacid Promotional Expenses	1995-2006	VANDAELE EXPERT RPT. EX. 53
DTX164				Chart: Top 10 products by U.S. Sales	03/00/07	VANDAELE EXPERT RPT. EX. 32
DTX165				Internet Record Search: Orange Book Data	06/15/07	TVL 064810-64845
DTX166				Press Release *"Prilosec OTC Launch Off & Running: Strongest Start of Any New P&G Brand Ever"*	09/22/03	TVL 064852
DTX167				Proton Pump Inhibitors Preauthorization Criteria, BlueCross BlueShield of Nebraska	04/20/07	TVL 069311- 69316
DTX168				Publication Entitled *"The $800 Million Pill, the Truth Behind the Cost of New Drugs"*	06/18/07	TVL 064785-64809
DTX169				Publication Entitled *"A Homerun for American Home,"* by Seiden	00/00/00	TVL 065619- 65624
DTX170				Publication Entitled *"Abbreviated Drug Class Review: Proton Pump Inhibitors, Pharmacy Benefits Management Strategic Healthcare Group,"* by Goodman	07/00/01	TVL 069325-69336
DTX171				Publication Entitled *"Advertising & Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs,"* The Journal of Law & Economics, by Rizzo	04/00/99	TVL 065198-65212
DTX172				Publication Entitled *"CIGNA Healthcare Coverage Position re: Proton Pump Inhibitor Therapy"*	06/15/06	TVL 064941-64950
DTX173				Publication Entitled *"Colitis Due to Clostridium Difficile Toxins: Underdiagnosed, Highly Virulent, & Nosocomial,"* by Fordtran	00/00/06	TVL 065505- 65514
DTX174				Publication Entitled *"Commercial & Pipeline Perspectives: Upper GI Disorders,"* by Datamonitor	10/00/04	TVL 065614- 65618
DTX175				Publication Entitled *"Demand Effects of Recent Changes in Prescription Drug Promotion,"* by Kaiser Family Foundation	06/00/03	TVL 064679-64714
DTX176				Publication Entitled *"Direct to Consumer Advertising & Prescription Choice,"* by Iizuka & Jin	04/04/05	TVL 065457- 65476
DTX177				Publication Entitled *"Drug Digest: Proton Pump Inhibitors"*	00/00/00	TVL 064536-64537
DTX178				Publication Entitled *"Drug Digest: Antacids"*	00/00/00	TVL 064538-64539
DTX179				Publication Entitled *"Drug Firms, Stymied in the Lab, Become Marketing Machines,"* by Harris	07/06/00	TVL 065359-65365

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX180				Publication Entitled *"Entry Order as a Consideration for Innovation Strategies,"* Nature Reviews Drug Discovery, by Cohen	03/10/06	TVL 065539- 65547
DTX181				Publication Entitled *"Esomeprazole (Nexium): A New Proton Pump Inhibitor*," by Leonard	08/00/01	TVL 069317-69319
DTX182				Publication Entitled *"Federal Panel Backs Prilosec for Over-the-Counter Sales,"* by Caroll	06/22/02	TVL 064676-64678
DTX183				Publication Entitled *"Generic Pharmaceutical Industry Review,"* by Fletcher	07/15/04	TVL 065135-65190
DTX184				Publication Entitled *"Heading Off Heartburn"*	06/13/07	TVL 064620-64623
DTX185				Publication Entitled *"Higher Prices from Entry: Pricing of Brand-Name Drugs, Dept of Agricultural & Resource Economics, UCB,"* by Perloff, Suslow & Seguin	00/00/96	TVL 065213-65253
DTX186				Publication Entitled *"How Increased Competition from Generic Drugs Has Affected Prices & Returns in the Pharmaceutical Industry"* by Congressional Budget Office	07/00/98	TVL 064992-65077
DTX187				Publication Entitled *"Industrial Market Structure & Economic Performance,"* 3rd Edition, by Scherer & Ross	00/00/90	TVL 065548- 65562
DTX188				Publication Entitled *"Industry Structure, Strategy, & Public Policy,"* Chapter 9, by Scherer	00/00/96	TVL 065078-65134
DTX189				Publication Entitled *"Information, Marketing, & Prices in the U.S. Antiulcer Drug Market, American Economic Review,"* by Berndt, Bui, Reily, & Urban	05/0//95	TVL 065191-65197
DTX190				Publication Entitled *"Just What the Patient Ordered? Direct-to-Consumer Advertising & the Demand for Pharmaceutical Products,"* by Wosinksa, Harvard Business School Marketing Research Papers	10/00/02	TVL 064715-64760
DTX191				Publication Entitled *"Medical Treatment of GERD"*	06/13/07	TVL 064617-64619
DTX192				Publication Entitled *"Network Effects & Diffusion in Pharmaceutical Markets: Antiulcer Drugs,"* by Berndt, Pindyck & Azoulay	03/00/99	TVL 065563- 65595
DTX193				Publication Entitled *"Now Available Without a Prescription,"* by Nordenberg	06/13/07	TVL 064604-64609
DTX194				Publication Entitled *"Persistence in Prescriptions of Branded Drugs,"* by Rich & Horn	10/02/03	TVL 065596-65613

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX195				Publication Entitled *"Pharmaceutical Economics & Policy,"* by Schweitzer	00/00/97	TVL 065366-65369
DTX196				Publication Entitled *"Prices, Profits, & Innovation: Examining Criticisms of New Psychotropic Drugs' Value,"* by Huskamp	00/00/06	TVL 064930-64940
DTX197				Publication Entitled *"Prilosec OTC – How Does It Compare to Zantac 75, Pepcid AC, & Other Over-the-Counter Heartburn Remedies?"*	06/14/07	TVL 064668-64675
DTX198				Publication Entitled *"Prilosec's Maker Switches to Nexium, Thwarting Generics,"* by Harris	06/06/07	TVL 064610-64616
DTX199				Publication Entitled *"Proton Pump Inhibitors,"* by McDonagh & Carson	07/00/06	TVL 064258-64353
DTX200				Publication Entitled *"Returns on Research & Development for 1990's New Drug Introductions,"* by Grabowski, Vernon, & DiMasi	00/00/02	TVL 064951-64969
DTX201				Publication Entitled *"Santarus Reports First Quarter 2007 Financial Results"*	05/01/07	TVL 064906-64908
DTX202				Publication Entitled *"Takeda Abbott Pharmaceuticals (TAP) in 2002,"* by Duke School of Business	11/00/03	TVL 069337-69352
DTX203				Publication Entitled *"The Big Squeeze,"* by Hisey	10/01/04	TVL 064778-64784
DTX204				Publication Entitled *"The Effect of Prescription Drug Advertising on Doctor Visits,"* by Iizuka & Jin	00/00/05	TVL 065477-65504
DTX205				Publication Entitled *"The Long Shadow of Patent Expiration: Generic Entry & RX to OTC Switches,"* by Berndt, Kyle, & Ling	01/17/02	TVL 065370-65418
DTX206				Publication Entitled *"The Pink Sheet,"* pg. 23	11/22/04	TVL 065286
DTX207				Publication Entitled *"The Prescription Generic Omeprazole DTC Launch,"* by McLinden, et al.	06/14/07	TVL 064846-64851
DTX208				Publication Entitled *"The United States' Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned?"* by Berndt	00/00/00	TVL 065424- 65456
DTX209				Publication Entitled *"Top 10 Selling Drugs in America… How the Drug Companies Deceive You: The Inside Story of Nexium,"* by Swidey	11/17/02	TVL 064540-64551
DTX210				Publication Entitled *"WebMD: Gastroesophageal Reflux Diseases in Infants & Children"*	00/00/03	TVL 064601-64603

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX211				Publication Entitled *"What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs?" The Journal of Industrial Economics,"* by Iizuka	09/00/04	TVL 065254-65285
DTX212				Publication Entitled *"Marketing, Product Differentiation, & Competition in the Market for Antiulcer Drugs,"* by King	09/16/02	TVL 064552-64600
DTX213				Publication Entitled *"Prescription Drugs & Mass Media Advertising, 2000,"* by Findlay, et al.	11/00/01	TVL 064761-64777
DTX214				Publication Entitled *"Proton Pump Inhibitor (PPI) Quarterly Sales Revenue by Product 2Q01-1Q07"*	00/00/01-00/00/07	VANDAELE EXPERT RPT. EX. 4
DTX215				Publication Entitled *"Steady But Not Stellar,"* IMS Business Health Watch, by Kumart & Zaugg	05/00/03	TVL 069320-69324
DTX216				Study: CME Enterprise Research Project Brochure	00/00/00	TVL 065515- 65538
DTX217				Zegerid Presentation Brochure	05/23/07	TVL 064853-64880
DTX218				Expert Report of R. Hirsch	06/26/07	HIRSCH DEP. EX. 5
DTX219				Curriculum Vitae of R. Hirsch	00/00/00	HIRSCH EXPERT RPT. EX. A
DTX220				Citations Used in Expert Report of Hirsch	00/00/00	HIRSCH EXPERT RPT. EX. B
DTX221				PSL Report: Evaluation of Compounds A & B Inhibition of Indomethacin Induced Gastric Mucosal Lesions in Rats	00/00/00	PSL 0001-21
DTX222				PSL Report: Effect of Compound Against Indomethacin Induced Gastric Mucosal Lesions in Rats	00/00/00	PSL 0022-27
DTX223				PSL Report: Effect of Compound D Against Indomethacin Induced Gastric Mucosal Lesions in Rats	00/00/00	PSL 0028-36
DTX224				PSL Data cited in expert report of R. Hirsch	00/00/00	HIRSCH EXPERT RPT. EX. D
DTX225				Takeda Data cited in expert report of R. Hirsch	00/00/00	HIRSCH EXPERT RPT. EX. E
DTX226				Publication Entitled *"Form Biostatistical Analysis,"* by Zar	00/00/84	HIRSCH DEP. EX. 1
DTX227				Publication Entitled *"Dynamics of Protozoan Population Density, Plasma Glutamic Oxalacetic Transaminase & Plasma Bilirubin Concentrations During Histomoniasis in Turkeys,"* by Hirsch	03/22/78	HIRSCH DEP. EX. 12
DTX228				Publication Entitled *"Studying a Study & Testing a Test,"* by Riegelman & Hirsch	00/00/96	HIRSCH DEP. EX. 13

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX229				Publication Entitled *"Using Confidence Intervals Around Individual Means to Assess Statistical Significance Between Two Means,"* by Julious	00/00/04	HIRSCH DEP. EX. 14
DTX230				PSL - SOP Deviation	01/03/07	PSL 0087-89
DTX231				Transcript of Dr. Hirsch's Videotaped Deposition	08/18/05	TVL 069153-69278
DTX232				Publication Entitled *"Statistical First Aid Interpretation of Health Research Data,"* Chapter 7, by Hirsch & Riegelman	00/00/92	HIRSCH DEP. EX. 3
DTX233				PSL - Table 1, Effect of Compound C Against Indomethacin Induced Gastric Antral Lesions & Attached Documents	00/00/00	PSL 0462-465
DTX234				Publication Entitled *"Introduction to Biostatistics, Part 6, Correlation & Regression,"* by Gaddis & Gaddis	12/12/90	HIRSCH DEP. EX. 6
DTX235				Publication Entitled *"Applied Regression Analysis & Other Multivariable Methods,"* Chapter 5 & 6, by Kleinbaum, Kupper, & Muller	00/00/00	TVL 066071-66081
DTX236				Publication Entitled *"Statistics Review 7, Correlation & Regression,"* by Bewick, Cheek, & Ball	11/05/03	HIRSCH DEP. EX. 8
DTX237				Publication Entitled *"Analyzing Data with GraphPad Prism,"* by Motulsky	00/00/99	HIRSCH DEP. EX. 9
DTX238				Excerpts from Lab Notebook	00/00/00	TAKEDA 639117; TAKEDA 642666-667; TAKEDA 642702-706; TAKEDA 642708; TAKEDA 642781; TAKEDA 642785; TAKEDA 642789; TAKEDA 649115-116; TAKEDA 649123-124; TAKEDA 638780-781; TAKEDA 638808-809; TAKEDA 639115; TAKEDA 642672-673; TAKEDA 649135-136
DTX239				Publication Entitled *"Mathematical Statistics with Applications,"* by Mendenhall, et al.	00/00/90	TVL 066082-66091
DTX240				Publication Entitled *"Probabilities of the Type I Errors of the Welch Tests for the Behrens-Fisher Problem,"* by Wang	09/00/71	TVL 066093-66096

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX241				PSL - Evaluation of Test Agent Inhibition Against Indomethacin Induced Gastric Mucosal Irritation: Rats	00/00/00	PSL 0043-49
DTX242				PSL - Study 20637: Indomethacin Induced Gastric Lesions	00/00/00	PSL 0058
DTX243				PSL - Study Notes	12/15/06	PSL 0094-95
DTX244				PSL - Raw Data Gastric Lesions	12/06/06	PSL 0466-561
DTX245				PSL - Bodyweight & Dosing Sheet	12/08/06	PSL 0443-444
DTX246				PSL - Raw Data Gastric Lesions	01/24/07	PSL 0606-661
DTX247				PSL – Bodyweight & Dosing Sheet	01/24/07	PSL 0587-588
DTX248				PSL - Study 21149: Dosing, Feed, & Obs	12/08/06	PSL 0445-447
DTX249				PSL - Study 21149: Dosing, Feed, & Obs	12/07/06	PSL 0458-460
DTX250				PSL - Study 21149: Dosing, Feed, & Obs	12/06/06	PSL 0454-456
DTX251				PSL - Bodyweight & Dosing Sheet	12/07/06	PSL 0440-441
DTX252				PSL - Bodyweight & Dosing Sheet	12/06/06	PSL 0434-438
DTX253				PSL - Bodyweight & Dosing Sheet	01/24/07	PSL 0592-593
DTX254				PSL - Study 21411: Dosing, Feed, & Obs	01/2/407	PSL 0589-591
DTX255				PSL - Study 21411: Dosing, Feed, & Obs	01/25/07	PSL 0594-596
DTX256				PSL - Bodyweight & Dosing Sheet	10/13/06	PSL 0166-171
DTX257				PSL - Individual Animal Data Sheet	10/13/06	PSL 0172-308
DTX258				PSL - Raw Data Gastric Lesions	10/13/06	PSL 0335-399
DTX259				Evaluation of Details from Study 20637 Indomethacin Induced Gastric Lesions	00/00/00	PSL 0050-57
DTX260				Safety Data Sheets from Organix	11/29/06	ORG 0001-74
DTX261				Publication Entitled *"Pharmacological Profile of the Thyroid Hormone Receptor Antagonist NH3 in Rats,"* by Grover, et al.	04/13/07	DONG DEP. EX. 14
DTX262				PSL - Raw Data Gastric Lesions	09/16/06 09/19/06	PSL 0310-333
DTX263				Publication Entitled *"Gastroenterology: Indomethacin Produces Gastric Antral Ulcers in Refed Rats"* by Satoh	12/00/81	PSL 0112-119
DTX264				PSL - Protocol Amendment to Study 20637	10/13/06	PSL 0059-81
DTX265				PSL - Protocol Deviation to Study 20637	12/20/06	PSL 0082-86
DTX266				U.S. Patent 4,265,900	05/05/81	JACOBY DEP. EX. 2
DTX267				Publication Entitled *"The Mechanism of Action of the Gastric Acid Secretion Inhibitor Omeprazole,"* Journal of Medicinal Chemistry, by Lindberg	08/00/86	LIPINISKI 0815-817
DTX268				Inhibition of Indomethacin Induced Antral Ulcers	00/00/00	PSL 0401-411

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX269				Study 21149 Excerpts: Evaluation of Test Agent Inhibition Against Indomethacin Induced Gastric Mucosal Irritation: Rats	12/08/06	PSL 0462-465
DTX270				PSL - Raw Data Gastric Lesions	12/07/06	PSL 0502-537
DTX271				PSL - Raw Data Gastric Lesions	12/08/06	PSL 0538-561
DTX272				Organizational Structure - Generic R&D	00/00/00	DICAPUA DEP. EX. 1
DTX273				30(b)(6) Notice of Deposition of Takeda to Teva	11/17/06	DICAPUA DEP. EX. 2
DTX274				E-mail from S. DiCapua to B. Iozefzon & K. Cohen	09/07/02	TVL 052763
DTX275				ANDA #77-255 - Section XV.2 – Analytical Methods: Drug Product	07/04/04	TVL 007573-7594
DTX276				U.S. Patent Application Publication No. US 2005/0214371 A1	09/29/05	DICAPUA DEP. EX. 7
DTX277				U.S. Patent Application Publication No. US 2005/0214372 A1	09/29/05	DICAPUA DEP. EX. 8
DTX278				30(b)(6) Notice of Deposition of Takeda to Teva	11/17/06	ERICKSON DEP. EX. 1
DTX279				ANDA #77-255 – Lansoprazole – Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	00/00/00	TVL 000001-21
DTX280				ANDA #77-255 – Section VI – Bioavailability / Bioequivalence	07/01/04	TVL 000223-261
DTX281				ANDA #77-255 – Lansoprazole – Pre-Approval Correspondence	12/05/05	TVL 008271-8293
DTX282				Letter from P. Erickson to FDA	12/14/06	TVL 062439-62508
DTX283				ANDA #77-255 – Bioequivalency Amendment	02/06/06	TVL 028155-28156
DTX284				Letter from P. Erickson to FDA	01/17/07	ERICKSON DEP. EX. 7
DTX285				Teva Pharmaceuticals & Teva Pharmaceutical Industries Supplemental Responses & Objections to TAP's Interrogatory No. 3	12/12/06	FACKLER DEP. EX.. 11
DTX286				E-mail from P. Fackler to G. DeRosa	07/28/03	TVL 046731-733
DTX287				Teva Memorandum from B. Iosefzon to J. Hrakovsky	07/04/01	TVL 028941-953
DTX288				Series of Emails from N. Shterman to M. Boutin, et al.	11/25/04	TVL 034143-54
DTX289				ANDA #77-255 – Summary of Stability Studies	00/00/00	TVL 007716-17
DTX290				30(b)(6) Notice of Deposition of Takeda to Teva	11/17/06	FACKLER DEP. EX.. 9
DTX291				Lab Notebook No. BPG-07-012	00/00/00	TVL 069861-69863
DTX292				Analysis of Samples Report from Materials Research Laboratories	00/00/00	HIRT 0048-68
DTX293				Raman Analysis Sheets	00/00/00	HIRT 0051-63; HIRT 0069
DTX294				Expert Report of Amidon	07/30/07	AMIDON DEP. EX. 1

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX295				Publication Entitled *"Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists,"* 2nd Edition, by Connors, Amidon & Kennon	00/00/86	AMIDON 0237-269
DTX296				Publication Entitled *"Stabilization of a New Antiulcer Drug Lansoprazole in the Solid Dosage Forms,"* by Tabata, Makino, Kashihara, Hirai, Tiamori & Taguchi	00/00/92	BYRN 0318-328
DTX297				Publication Extract Entitled *"Handbook of Pharmaceutical Excipients,"* 1st Edition	00/00/86	AMIDON 0270-280
DTX298				Curriculum Vitae of Amidon	00/00/00	AMIDON 0001-80
DTX299				In re Omeprazole Patent Litigation	00/00/00	AMIDON 0101-225
DTX300				Expert Report of D. Bugay	06/27/07	BUGAY DEP. EX. 1
DTX301				Supplemental Expert Report of D. Bugay	07/17/07	BUGAY DEP. EX. 2
DTX302				Color-coded Charts from Bugay Expert Report	00/00/00	BUGAY 196.001-196.050
DTX303				ANDA #77-255 – Ingredient List	00/00/00	BUGAY 0131
DTX304				Collected Spectra from Position Three	00/00/00	BUGAY 0034
DTX305				Charts: Collection of 13 Comparison Graphs re: Teva 30mg Lansoprazole Granules & Magnesium Carbonate	00/00/00	BUGAY 0063-75
DTX306				Chart: Comparison Graph of the Spatial Positions in Which Lansoprazole & Magnesium Carbonate are Located on Teva's 30mg Lansoprazole	00/00/00	BUGAY 0062
DTX307				Confocal Raman-Spectroscopy: Analytical Approach to Solid Dispersions & Mapping of Drugs	04/12/99	BUGAY 0124-128
DTX308				Correlates the Spatial Position to the Spectrum for the Other Fourteen Raman Maps that were Collected on Various Granules	00/00/00	BUGAY 0030-33
DTX309				Designation of Raman Map Filenames that are Associated with Each Spatial Region	00/00/00	BUGAY 0028
DTX310				EDX Map Detecting a Band of Fluorine	00/00/00	BUGAY 0090
DTX311				EDX Map of Lansoprazole with that of Magnesium Obtained from the Subtraction Procedure.	00/00/00	BUGAY 0094
DTX312				EDX Map of the 1st Granule in Which any Spatial Positions of Silicon have been Subtracted from Spatial Positions Indicative of Magnesium.	00/00/00	BUGAY 0093
DTX313				EDX Maps Collected for the 1st Granule	00/00/00	BUGAY 0077-85
DTX314				EDX Maps Collected for the 2nd Granule	00/00/00	BUGAY 0086-87
DTX315				EDX Maps Collected for the 3rd Granule	00/00/00	BUGAY 0088-89
DTX316				Granule 4, 6:00 Position, Map 222145-1	00/00/00	BUGAY 0057

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX317				Optical Image of a Granule Surface	00/00/00	BUGAY 0026
DTX318				Optical Image of One of Teva's 30mg Lansoprazole Granules that has been Prepared for Raman Spectroscopic Mapping Analysis	00/00/00	BUGAY 0027
DTX319				Output of Profile Fitting Procedure	00/00/00	BUGAY 0035
DTX320				Overlay of the 36 Spectra that were Collected for Granule #4, 6:00 Position	00/00/00	BUGAY 0029
DTX321				Overlay of the Raman Spectra of Each Granule Component on an Absolute Intensity Scale	00/00/00	BUGAY 0025
DTX322				Overlay Plot of the Six Pharmaceutical Components	00/00/00	BUGAY 0024
DTX323				Photograph of Scanning Electron Microscope Equipped with an X-ray Detector	00/00/00	BUGAY 0017
DTX324				Photograph of 5th Raman Map Collected from First Granule	00/00/00	BUGAY 0058
DTX325				Photograph of 5th Raman Map Collected from First Granule with Labels	00/00/00	BUGAY 0059
DTX326				Photograph Showing Magnesium Present in the Intermediate Layer	00/00/00	BUGAY 0092
DTX327				Publication Entitled *"Applications of Vibrational Spectroscopy in Pharmaceutical Research & Development,"* by Pivonka, et al.	00/00/07	BUGAY 0096-123
DTX328				Publication Entitled *"Raman & EDXRF Chemical Imaging for Formulation Process Development & Quality Control,"* by Clark, Whitley, Mamedov, Adar, Lewis & Lee	06/00/05	BYRN 0252-253
DTX329				Raman Spectrometer with a Microscope	00/00/00	BUGAY 0016
DTX330				Raman Spectrum Acquired for the Lansoprazole API	00/00/00	BUGAY 0018
DTX331				Raman Spectrum for Hypromellose	00/00/00	BUGAY 0021
DTX332				Raman Spectrum for Magnesium Carbonate	00/00/00	BUGAY 0019
DTX333				Raman Spectrum for Sugar	00/00/00	BUGAY 0023
DTX334				Raman Spectrum for Talc	00/00/00	BUGAY 0022
DTX335				Raman Spectrum for Titanium Dioxide	00/00/00	BUGAY 0020
DTX336				Raw Data – CD	00/00/00	BUGAY 0132
DTX337				Representation of Detectable Lansoprazole as a Function of Spatial Position	00/00/00	BUGAY 0036
DTX338				SEM Image for Each Granule	00/00/00	BUGAY 0076
DTX339				Spatial Position vs. Concentration Graph for Lansoprazole	00/00/00	BUGAY 0060

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX340				Spatial Position vs. Concentration Graph for Magnesium Carbonate	00/00/00	BUGAY 0061
DTX341				Spatial Positions Upon the Surface of the First Granule in Which Magnesium is Present	00/00/00	BUGAY 0091
DTX342				Zoomed in View of the Granule Map of Magnesium Carbonate & Lansoprazole	00/00/00	BUGAY 0095
DTX343				Photograph of Opened Bottles of Lansoprazole DR USP 15mg & 30mg	00/00/00	BUGAY 0015
DTX344				Curriculum Vitae of D. Bugay	00/00/00	BUGAY 0001-13
DTX345				Analogous Graph with Indications as to the Spatial Position of Magnesium Carbonate in Teva's Granule #4 Map 222145-1	00/00/00	BUGAY 0056
DTX346				Photograph of Unopened Bottles of Lansoprazole DR USP 15mg & 30mg	00/00/00	BUGAY 0014
DTX347				Brostrom Lab Notebook 2726	00/00/00	BUGAY 0166-194 BUGAY 0037-55
DTX348				Complete EDX Results – CD	00/00/00	BUGAY 00195
DTX349				Composite Map for Each of the Four 15mg Granule & One 30mg Granule	00/00/00	BUGAY 0161
DTX350				EDX Map of the 15mg Granules & 30mg Granule in Which any Spatial Positions of Silicon have been Subtracted from Spatial Positions Indicative of Magnesium.	00/00/00	BUGAY 0164-165
DTX351				EDX Maps of 4 Granules from Teva's 15mg Capsules & One Granule from Teva's 30mg Capsules	00/00/00	BUGAY 000160
DTX352				Experimental Details for Each Line Map on the 15mg Granules & the 30mg Granules	00/00/00	BUGAY 0148-149
DTX353				Fluorine & Magnesium EDX Images from the Four 15mg Granules & the One 30mg Granule	00/00/00	BUGAY 0162-163
DTX354				Representations of Detectable Lansoprazole & Magnesium Carbonate as a Function of Spatial Position	00/00/00	BUGAY 0151-159
DTX355				Representative, Color Optical Image of a 15mg Granule Surface	00/00/00	BUGAY 0133-136
DTX356				Results of 30mg Granules Analysis	00/00/00	BUGAY 0137-147
DTX357				The Three Lines of Spectral Acquisition	00/00/00	BUGAY 0150
DTX358				Expert Report of S. Byrn	06/27/07	AMIDON DEP. EX. 3
DTX359				Supplemental Expert Report of S. Byrn	07/17/07	BYRN DEP. EX. 2
DTX360				Declaration of S. Byrn	09/11/07	BYRN DEP. EX. 3
DTX361				Curriculum Vitae of S. Byrn	00/00/00	BYRN 0001-31

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX362				Publication Entitled *"Solid-State Chemistry of Drugs,"* by Byrn	00/00/82	BYRN DECLARATION EX. I
DTX363				Photographs - EDX Spectra from Bugay Exp. Report	00/00/00	BYRN 0254-258
DTX364				Prevacid Drug Information Sheet	09/00/06	BYRN 0282-317
DTX365				ANDA #77-255 – Section VII – Components & Composition Statements	07/01/04	BYRN 0032-191
DTX366				Chart: Lansoprazole DR 30mg Capsules Batch Summary	00/00/00	TVL 035179-184
DTX367				Excerpts from S. DiCapua Deposition from Byrn Report	02/07/07	BYRN 0243-251
DTX368				Charts: Intermixing of Lansoprazole & Magnesium Carbonate Shown in Line Maps from Bugay Report	00/00/00	BYRN 0259-269
DTX369				Publication Entitled *"Drug-Excipient Incompatibility Studies of the Dipeptide Angiotensin-Converting Enzyme Inhibitor, Moexipril Hydrochloride: Dry Powder vs. Wet Granulation,"* by Gu, Strickley, Chi & Chowhan	10/23/89	BYRN 0270-274
DTX370				Publication Entitled *"Effect of Salt Form on Chemical Stability of an Ester Prodrug of a Glycoprotein IIb/IIIa Receptor Antagonist in Solid Dosage Forms,"* by Badawy	04/18/01	BYRN 0275-281
DTX371				ANDA #77-255 – Section XII – In-Process Controls	08/00/04	BYRN 0329-607
DTX372				ANDA #77-255 – Section VI.3 – Dissolution	02/27/04	BYRN 0608-626
DTX373				ANDA #77-255 – Lansoprazole 15mg Strength	07/00/04	BYRN 0057-180
DTX374				Expert Report of B. Fennerty	07/30/07	
DTX375				Curriculum Vitae of B. Fennerty	09/00/06	FENNERTY DEP. EX. 11
DTX376				Data & Information Considered by B. Fennerty	00/00/00	FENNERTY DEP. EX. 4
DTX377				Publication Entitled *"Drug Class Review on Proton Pump Inhibitor"*	7/00/06	TVL 063419-63514
DTX378				Systematic Review: Direct Comparative Trials at the Efficacy of Proton Pump Inhibitors in the Management of Gastro-oesophageal Reflux Disease & Peptic Ulcer Disease	07/11/03	FENNERTY 0445-454
DTX379				Publication Entitled *"Gastrooesophageal Reflux Disease"*	00/00/00	FENNERTY DEP. EX. 9
DTX380				Publication Entitled *"Early Heartburn Relief with Proton Pump Inhibitors: A Systematic Review & Meta-analysis of Clinical Trials"*	00/00/05	FENNERTY 0401-411
DTX381				Publication Entitled *"Med-Psych Drug-Drug Interactions Update: Gastrointestinal Medications,"* by Wynn, et al.	02/00/07	FENNERTY 0455-461
DTX382				Publication Entitled *"Pharmacokinetics of Proton Pump Inhibitors in Children,"* by Litalien, et al.	00/00/05	FENNERTY 0375-400

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX383				Prevacid Drug Information	06/00/07	FENNERTY 0486-521
DTX384				Prevacid Marketing/Advertisements	00/00/00	TAP 273505-524; TAP 273655-669; TAP 273643-646
DTX385				Prilosec Drug Information Sheet	00/00/00	FENNERTY 0462-485
DTX386				Publication Entitled "*Comparing Lansoprazole & Omeprazole in Onset of Heartburn Relief: Results of a Randomized, Controlled Trial in Erosive Esophagitis Patients,"* by Richter, et al.	00/00/01	TVL 063687-63696
DTX387				Publication Entitled *"Fast Acid Control & Rapid Symptom Relief for Patients with Gastro-esophageal Reflux Disease – the Evidence from Proton Pump Inhibitor Studies"* by Bytzer	04/26/06	FENNERTY 0293-305
DTX388				Publication Entitled *"Gastroenterology: Lansoprazole vs. Omeprazole in Short-Term Treatment of Reflux Pesophagitis"*	09/28/92	FENNERTY 0327-333
DTX389				Publication Entitled *"Management of Heartburn in a Large, Randomized, Community-Based Study: Comparison of Four Therapeutic Strategies"*	00/00/01	FENNERTY 0334-340
DTX390				Publication Entitled *"pH, Healing Rate, & Symptom Relief in Patients with GERD,"* Yale Journal of Biology & Medicine	06/00/99	FENNERTY 0341-356
DTX391				Publication Entitled *"Systematic Review: Is There Excessive Use of Proton Pump Inhibitors in Gastro-oesophageal Reflux Disease?"* by Lee, et al.	09/24/04	FENNERTY 0364-374
DTX392				Top 200 Brand Name Drugs by Retail Dollars in 2006	00/00/06	FENNERTY 0522
DTX393				Publication *Entitled "What are the Alternative Approaches to the Long-Term Management of GERD?"* by Fennerty	00/00/05	FENNERTY 0321-326
DTX394				Publication Entitled *"Acid Inhibition on the First Day of Dosing: Comparison of Four Proton Pump Inhibitors,"* by Pantoflickova	12/30/02	FENNERTY 0419-426
DTX395				Publication from American Journal of Health-System Pharmacy	12/01/99	FENNERTY 0427-434
DTX396				U.S. Patent Application No. 07/014,303 – Declaration Under Rule 132	02/13/87	HAM 3522-25
DTX397				U.S. Patent Application No. 07/014,303 – Amendment Submitted Under 37 CFR 1.115	02/13/87	HAM 3515-3521
DTX398				U.S. Patent Application No. 07/014,303 – Reply Brief - USPTO Board of Appeals	08/13/90	HIRAI DEP. EX. 34
DTX399				Byrn Expert Certificate of Experimental Results	06/16/91	TAKEDA 380476-88

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX400				Kaneko Drawing	00/00/00	KANEKO DEP. EX. 41
DTX401				Kaneko Lab Notebook	00/00/00	TAKEDA 445983-446084
DTX402				Kaneko Lab Notebook	00/00/00	TAKEDA 446085-446188
DTX403				Kaneko Lab Notebook	00/00/00	TAKEDA 446189-446291
DTX404				Kaneko Lab Notebook	00/00/00	TAKEDA 446292-446396
DTX405				Kaneko Lab Notebook	00/00/00	TAKEDA 446397-446501
DTX406				Kaneko Lab Notebook	00/00/00	TAKEDA 446502-446605
DTX407				Kaneko Lab Notebook	00/00/00	TAKEDA 446606-446709
DTX408				Kaneko Lab Notebook	00/00/00	TAKEDA 446710-446813
DTX409				Kaneko Lab Notebook	00/00/00	TAKEDA 446814-446916
DTX410				Kaneko Lab Notebook	00/00/00	TAKEDA 446917-447024
DTX411				Expert Report of J. Kaunitz	08/01/07	KAUNITZ DEP. EX. 3
DTX412				Color Version of J. Kaunitz Report	00/00/00	KAUNITZ DEP. EX. 4
DTX413				Curriculum Vitae of J. Kaunitz	00/00/00	KAUNITZ DEP. EX. 2
DTX414				30(b)(6) Notice of Deposition of Teva to Takeda	11/17/06	KITAO DEP. EX. 1
DTX415				List of People Contacted by T. Kitao for Document Search	00/00/00	KITAO DEP. EX. 5
DTX416				Kitao Lab Notebook 1753	00/00/00	TAKEDA 638687-638797
DTX417				E-mail from J. Blake to P. Riesen, et al.	02/16/07	KITAO DEP. EX. 61
DTX418				Kitao Lab Notebook	00/00/00	TAKEDA 638798-638966
DTX419				Kitao Lab Notebook	00/00/00	TAKEDA 649039-649161
DTX420				Kitao Lab Notebook	00/00/00	TAKEDA 639072-639163
DTX421				Kubo Lab Notebook	00/00/00	TAKEDA 039372-39476
DTX422				Kubo Lab Notebook	00/00/00	TAKEDA 039477-39581
DTX423				Kubo Lab Notebook	00/00/00	TAKEDA 039582-39685
DTX424				Kubo Lab Notebook	00/00/00	TAKEDA 039686-39789
DTX425				Kubo Lab Notebook	00/00/00	TAKEDA 039790-39893
DTX426				Kubo Lab Notebook	00/00/00	TAKEDA 039894-40000
DTX427				Kubo Lab Notebook	00/00/00	TAKEDA 040001-40114
DTX428				Lab Notebook 2352	00/00/00	TAKEDA 051182-51184
DTX429				Expert Report of C. Lipinski	00/00/00	
DTX430				Second Expert Report of C. Lipinski	07/29/07	LENZ DEP. EX. 10
DTX431				Curriculum Vitae of C. Lipinski	06/18/07	LIPINSKI 0001-27
DTX432				Materials Reviewed by C. Lipinski	00/00/00	LIPINSKI 2714-2717

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX433				Teva's Responses to Takeda's 1st Set of Requests for Admission (Nos 1-3)	01/18/07	LIPINSKI 0142-146
DTX434				ANDA #77-255 – Section V – Labeling	00/00/00	LIPINSKI 0151-180
DTX435				U.S. Patent Certification Notice for the '098, 321, 560, 132 & 959 Patents	12/05/05	LIPINSKI 0218-229
DTX436				U. S. Patent Application to Market a New Drug: Lansoprazole	08/27/04	LIPINSKI 0147
DTX437				ANDA #77-255 – Section IV – Comparison: Generic Drug vs. Reference Listed Drug	00/00/00	LIPINSKI 0148-150
DTX438				ANDA #77-255 – Labeling Amendment	01/17/07	LIPINSKI 0181-217
DTX439				Byk Compound Reported in the '098 Patent in or about July 1984	07/00/84	LIPINSKI 1974-2186
DTX440				Comparative Stability Study for Lansoprazole & Omeprazole in Solid State	05/00/90	LIPINSKI 2678-2682
DTX441				Compounds Incorporating the Trifluoroethoxy Group with Pharmaceutical Activity – Compounds Before 1985	06/14/07	LIPINSKI 1331-1352
DTX442				Compounds Incorporating the Trifluoroethoxy Group with Pharmaceutical Activity – Compounds After 1985	06/14/07	LIPINSKI 1353-1389
DTX443				Compounds Incorporating Trifluoroethoxy at the 4-Position of the Pyridine Ring	05/17/05	LIPINSKI 1321-1330
DTX444				Publication Entitled *"Effect of Substituted Benzimidazoles on Acid Secretion in Isolated & Enriched Guinea Pig Parietal Cells,"* by Sewing, et al.	00/00/83	LIPINSKI 0956-959
DTX445				Publication Entitled *"Effects of Substituted Benzimidazole (H 149/94) on Gastric Acid Secretion in Humans,"* by Olbe, et al.	00/00/82	LIPINSKI 0846-851
DTX446				Lab Notebook – AG Screening Data	00/00/00	LIPINSKI 2187-2400
DTX447				Publication *Entitled "Omeprazole, a Specific Inhibitor of Gastric (H-K)-ATPase, is a H-activated Oxidizing Agent of Sulfhydryl Groups,"* by Eim, et al.	04/25/86	LIPINSKI 0755-762
DTX448				Publication Entitled *"Pharmaceutical Innovation by the Seven UK-owned Pharmaceutical Companies (1964-1985),"* by Prentis, et al.	10/23/87	LIPINSKI 0867-876
DTX449				Publication Entitled *"Pharmacology & Toxicology of Omeprazole – with Special Reference to the Effects on the Gastric Mucosa,"* Carlsson, et al.	00/00/00	LIPINSKI 0623-630

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX450				Publication Entitled *"2-[[(4-Amino-2-pyridyl) methyl] sulfinyl] benzimidazole H+/K+-ATPase Inhibitors: The Relationship Between Pyridine Basicity, Stability, & Activity,"* by Ife, et al.	12/12/88	LIPINSKI 0748-754
DTX451				Publication Entitled *"Drugs & People: Molecular Modification of Prototype Drugs"*	00/00/00	LIPINSKI 0687-690
DTX452				Publication Entitled *"Is There An Optimal Degree of Acid Suppression for Healing of Duodenal Ulcers?"*	08/00/90	LIPINSKI 0691-697
DTX453				Publication *Entitled "Structure of 5-Methoxy-{[4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benzimidazole (Omeprazole),"* by Ohishi, et al.	04/10/89	LIPINSKI 0843-845
DTX454				Publication Entitled *"Structure-Activity Relationships of Omeprazole Analogues & Their Mechanism of Action,"* Linberg, et al.	10/00/87	LIPINSKI 0818-821
DTX455				Publication *Entitled "Synthesis of 2-[[(4-Fluoroalkoxy-2-pyridyl] sulfinyl]-1H-benzimidazoles as Antiulcer Agents,"* by Kubo, et al.	10/00/90	LIPINSKI 0564-570
DTX456				Publication Entitled *"Tetrahedron Report No. 31: Introduction of Fluorine Into Organic Molecules: Why & How,"* by Schlosser	03/09/77	TVL 062414-62429
DTX457				Publication *Entitled "The Pharmacology of the Gastric Pump: The H+,K+ ATPase 1,2,"* by Sachs, et al.	00/00/95	LIPINSKI 2683-2713
DTX458				Publication Entitled *"The Protective Role of Gastric Acid,"* by Hunt	00/00/88	LIPINSKI 0742-747
DTX459				Publication *Entitled "The Treatment of Gastric Ulcer with Antisecretory Drugs: Relationship of Pharmacological Effect to Healing Rates,"* by Howden, et al.	05/00/88	LIPINSKI 0720-725
DTX460				Publication Entitled *"Toxicological Studies on Omeprazole,"* by Ekman, et al.	00/00/85	LIPINSKI 0698-704
DTX461				Lab Notebook – AG Compounds Table	00/00/00	TAKEDA 050988-51252
DTX462				Certified Translation of TAKEDA 040730	07/03/07	LIPINSKI 1171-1173
DTX463				Certified Translation of TAKEDA 040780	07/03/07	LIPINSKI 1174-1176
DTX464				Certified Translation of TAKEDA 040832-833	07/03/07	LIPINSKI 1177-1181
DTX465				Certified Translation of TAKEDA 040834	07/03/07	LIPINSKI 1182-1184
DTX466				Certified Translation of TAKEDA 040843	07/03/07	LIPINSKI 1185-1187
DTX467				Certified Translation of TAKEDA 040859-860	07/03/07	LIPINSKI 1188-1192
DTX468				Certified Translation of TAKEDA 040852	07/03/07	LIPINSKI 1222-1224

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX469				Certified Translation of TAKEDA 040861	07/03/07	LIPINSKI 1225-1227
DTX470				Certified Translation of TAKEDA 040869	07/03/07	LIPINSKI 1228-1230
DTX471				Certified Translation of TAKEDA 040875-876	07/03/07	LIPINSKI 1231-1235
DTX472				Certified Translation of TAKEDA 436710-733	07/03/07	LIPINSKI 1272-1320
DTX473				Certified Translation of TAKEDA 040893	07/03/07	LIPINSKI 1193-1195
DTX474				Certified Translation of TAKEDA 040901	07/03/07	LIPINSKI 1196-1198
DTX475				Certified Translation of TAKEDA 040909	07/03/07	LIPINSKI 1199-1201
DTX476				Certified Translation of TAKEDA 040924	07/03/07	LIPINSKI 1202-1204
DTX477				Certified Translation of TAKEDA 040931	07/03/07	LIPINSKI 1205-1207
DTX478				Certified Translation of TAKEDA 040938	07/03/07	LIPINSKI 1208-1210
DTX479				Certified Translation of TAKEDA 040944	07/03/07	LIPINSKI 1211-1213
DTX480				Certified Translation of TAKEDA 040951-952	07/03/07	LIPINSKI 1214-1218
DTX481				Certified Translation of TAKEDA 040953	07/03/07	LIPINSKI 1219-1221
DTX482				Certified Translation of TAKEDA 040877	07/03/07	LIPINSKI 1236-1238
DTX483				Certified Translation of TAKEDA 040886	07/03/07	LIPINSKI 1239-1241
DTX484				Certified Translation of TAKEDA 040945	07/03/07	LIPINSKI 1242-1244
DTX485				Lab Notebook in Japanese	1983-1984	LIPINSKI 1768-1973
DTX486				Publication Entitled *"Simultaneous High Performance Liquid Chromatographic Analysis of Omeprazole & its Sulphone & Sulphide Metabolites in Human Plasma & Urine,"* by Milaly, et al.	07/13/83	LIPINSKI 0829-837
DTX487				Publication Entitled *"Acid Activation of (H+-K+)_ATPase Inhibiting 2-(2-Pyridylmethyl-sulphinyl)benzimidazoles: Isolation & Characterization of the Thiophilic 'Active Principle' & its Reactions,"* by Figala	09/02/85	LIPINSKI 0705-707
DTX488				Publication Entitled *"Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents,"* by Beasocon	05/29/97	LIPINSKI 0631-639
DTX489				Publication Entitled *"(H+K+)-ATPase Inhibiting 2-[(2-Pyridylmethyl) sulfinyl]benzimidazoles: A Novel Series of Dimethoxypyridyl-Substituted Inhibitors with Enhanced Selectivity. The Selection of Pantoprazole as a Clinical Candidate,"* by Kohl, et al.	00/00/92	LIPINSKI 0763-771
DTX490				Publication Entitled *"2-((2-Pyridylmethyl) Sulfinyl) Benzimidazoles: Acid Sensitive Suicide Inhibitors of the Proton Transport System in the Parietal Cell,"* by Rackur, et al.	04/16/85	LIPINSKI 0877-884

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX491				Publication Entitled *"Cimetidine: A Review of its Pharmacological Properties & Therapeutic Efficacy in Peptic Ulcer Disease,"* by Brogden, et al.	00/00/78	LIPINSKI 0648-686
DTX492				Publication Entitled *"Analogue-based Drug Discovery: The Development of a New Proton-Pump Inhibitor: The Case History of Pantoprazole,"* by Fischer & Ganellin	00/00/06	LIPINSKI 0921-944
DTX493				Publication Entitled *"Aromatic Substituent Constants for Structure – Activity Correlations"* by Hansch, et al.	06/18/73	LIPINSKI 0714-719.004
DTX494				Publication Entitled *"The Chemically Elegant Proton Pump Inhibitors,"* by Roche	10/15/06	LIPINSKI 0893-903
DTX495				Publication Entitled *"Biotransformation & Elimination of 14C-Flecainide Acetate in Humans,"* by McQuinn, et al.	03/08/84	LIPINSKI 0822-828
DTX496				Publication Entitled *"Analogue-based Drug Discovery: Esomeprazole in the Framework of Proton-Pump Inhibitor Development,"* by Fischer & Ganellin	00/00/06	LIPINSKI 0780-814
DTX497				Certified Translation of Takeda 436694-709	07/11/07	LIPINSKI 1245-1271
DTX498				Publication Entitled *"Proton Pump Inhibitors,"* by Olbe	00/00/99	LIPINSKI 0972-997
DTX499				Publication Entitled *"Dissociation Constants of Organic Bases in Aqueous Solution, Supplement 1972,"* by Perrin	00/00/72	TVL 065713-65839
DTX500				Publication Entitled *"Proton Pump Inhibitors,"* by Olbe	00/00/99	LIPINSKI 0998-1017
DTX501				Publication Entitled *"Chemistry of Covalent Inhibition of the Gastric (H+, K+)-ATPase by Proton Pump Inhibitors,"* by Shin, et al.	06/04/04	LIPINSKI 0960-971
DTX502				Publication Entitled *"A Proton-Pump Inhibitor Expedition: The Case Histories of Omeprazole & Esomeprazole,"* by Olbe, et al.	02/00/03	LIPINSKI 0852-859
DTX503				Publication Entitled *"The Continuing Development of Proton Pump Inhibitor's with Particular Reference to Pantoprazole"* by Huber, et al.	02/21/95	LIPINSKI 0726-741
DTX504				Publication Entitled *"Structure Activity Relationships of Substituted Benzimidazoles,"* by Brandstrom, et al.	00/00/85	TVL 059671-59679
DTX505				Publication Entitled *"Molecular Modeling of SCH28080 Binding to the Gastric H,K-ATPase & MgATP Interactions with SERCA- & Na,K-ATPases,"* by Munson, et al.	00/00/03	LIPINSKI 0838-842
DTX506				Publication Entitled *"Inhibition of Gastric Acid Secretion by Omeprazole in the Dog & Rat,"* by Larsson, et al.	10/00/83	LIPINSKI 0772-779

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX507				Publication Entitled *"Safety Profile of the Proton-Pump Inhibitors,"* American Journal of Health System Pharmacy, by Reilly	12/06/99	LIPINSKI 0885-892
DTX508				Certified Translation of Monthly Report December 1984	12/01/84	TAKEDA 040986-992
DTX509				Certified Translation of Central Research Division Monthly Report October 1983	10/01/83	TAKEDA 040866-873
DTX510				Certified Translation of Central Research Division Monthly Report November 1983	11/01/83	TAKEDA 040874-882
DTX511				Certified Translation of Central Research Division Monthly Report August 1984	08/01/84	TAKEDA 040943-950
DTX512				Certified Translation of Takeda 047495	00/00/00	TAKEDA 047495
DTX513				Certified Translation of Takeda 422781	00/00/00	TAKEDA 422781
DTX514				Certified Translation of Takeda 422831	00/00/00	TAKEDA 422831
DTX515				Japanese Patent Application No. 61-29567	02/13/86	MAKINO DEP. EX.27
DTX516				Japanese Patent Application No. 61-38059	02/21/86	MAKINO DEP. EX.28
DTX517				Prevacid: Power Plus Versatility	00/00/00	TAP 273713-273720
DTX518				TAP Memorandum from J. Wargel to Distribution	10/10/94	TAP 000314-315
DTX519				Abbott Memorandum from J. Ackerman to Distribution	11/07/94	TAP 000552
DTX520				Prevacid Advertisement	00/00/00	TAP 273581-273602
DTX521				TAP R&D Committee Meeting Minutes	04/16/91	TAKEDA 493766-493772
DTX522				History on Formulation & Manufacturing Procedure for AG-1749 Capsules	06/00/92	TAKEDA 601019-601042
DTX523				Certified Translation of Monthly Report June 1985	06/01/85	TAKEDA 610685
DTX524				Certified Translation of Monthly Report July 1985	07/01/85	TAKEDA 610684
DTX525				Certified Translation of Monthly Report December 1985	12/01/85	TAKEDA 047455-456
DTX526				Certified Translation of Monthly Report December 1985	12/01/85	TAKEDA 610681
DTX527				Certified Translation of Monthly Report August 1986	08/01/86	TAKEDA 047535-536
DTX528				Tetsuro Tabata Deposition from Astra v. Takeda	03/15/94	TABATA DEP. EX. 9
DTX529				Expert Report of Whittle	07/26/07	WHITTLE DEP. EX. 1
DTX530				Curriculum Vitae of B. Whittle	00/00/00	WHITTLE 0001-80
DTX531				Materials Considered by B. Whittle	00/00/00	WHITTLE 2013-2016
DTX532				Pharmacological Profile of AG-1749, a (H-K) – ATPase	00/00/00	TAKEDA 100743
DTX533				Translation of Takeda Notebook - September 1984 Monthly Report	09/00/84	WHITTLE 0254-256
DTX534				Chart: Inhibition of IMAU Graph by AG-1749	00/00/00	WHITTLE 0547-562

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX535				Chart: Dose Response Curves Plotted by H. Satoh for the IMAU Experiments	00/00/00	TAKEDA 649161
DTX536				Publication Entitled *"Cytoprotection by Prostaglandins,"* by Robert	04/10/79	WHITTLE 0857-863
DTX537				Publication Entitled *"Drug Intelligence & Clinical Pharmacy"*	06/00/88	WHITTLE 0699-706
DTX538				Publication Entitled *"Effects of 2-(E-2-Decenoylamino)ethyl 2-(Cyclohexylethyl) Sulfide on Various Ulcer Models in Rats,"* by Kohda	07/00/91	WHITTLE 0707-710
DTX539				Publication Entitled *"Experimental Gastric Mucosal Injury,"* by Glarin & Szabo	02/00/92	WHITTLE 0623-629
DTX540				Publication Entitled *"Experimental Models of Gastric Ulceration & Injury,"* by Silen	00/00/88	WHITTLE 0917-924
DTX541				Publication Entitled *"Further Evidences on Gastric Cytoprotection Exerted by Pirenzepine,"* by Varin, et al.	00/00/84	WHITTLE 0977-989
DTX542				IMAU 1749	00/00/00	WHITTLE 0223
DTX543				Publication Entitled *"Indomethacin Produces Gastric Antral Ulcers in the Refed Rat"* by Satoh, et al.	00/00/81	WHITTLE 0871-877
DTX544				Publication Entitled *"Microcirculatory Disturbance in Indomethacin-Induced Intestinal Ulcer,"* by Miura, et al.	00/00/91	WHITTLE 0801-807
DTX545				Publication *Entitled "Nonsteriodal Anti-Inflammatory Drugs & Peptic Ulcer Disease,"* by Soll, et al.	02/15/91	WHITTLE 0925-937
DTX546				Publication Entitled *"Non-Steroidal Anti-Inflammatory Drug-Induced Gastric Damage in Experimental Animals: Underlying Pathological Mechanisms,"* by Trevethick, et al.	00/00/95	WHITTLE 0964-968
DTX547				Publication Entitled *"Possible Involvement of Hyperinsulinemia & Adrenergic Activation in the Pathogenesis of Indomethacin-Induced Antral Ulcers in Nonfasted Hamsters & Refed Rats,"* by Kuratani, et al.	07/24/92	WHITTLE 0731-735
DTX548				Publication *Entitled "Prevention & Healing of Experimental Indomethacin-induced Gastric Lesions: Effects of Ebrotidine, Omeprazole & Ranitidine,"* by Arroup, et al.	12/00/93	WHITTLE 0570-576
DTX549				Publication Entitled *"Principles & Practice of Gastroenterology & Hepatology"* by Kauff, Mari & Whittle	00/00/88	WHITTLE 1027-1038
DTX550				PSL - Bodyweight & Dosing Sheet	01/24/07	WHITTLE 1658-1659
DTX551				PSL - Bodyweight & Dosing Sheet	01/25/07	WHITTLE 1663-1664

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX552				Publication Entitled *"Close-Arterial Administration of the Thromboxane Mimetic U-46519 Induces Damage to the Rat Gastric Mucosa,"* by Esplugues & Whittle	02/00/88	WHITTLE 0234-240
DTX553				Publication Entitled *"Do Infiltrating Neutrophils Contribute to the Pathogenesis of Indomethacin Induced Ulceration of the Rat Gastric Antrum?"*	00/00/00	WHITTLE EXPERT RPT.
DTX554				Publication Entitled *"Gastric Anti-Secretory, Mucosal Protective, Anti-Pepsin & Anti-Heliocobacter Properties of Ranitidine Bismuth Citrate"* by Stables, et al.	02/08/93	WHITTLE 0938-947
DTX555				Publication Entitled *"Gastric Mucosal Contraction & Vascular Injury Induced by Indomethacin Precede Neutrophil Infiltration in the Rat"* by Anthony, et al.	04/18/96	WHITTLE 0563-569
DTX556				Publication Entitled *"Gastric Ulcer Formation & Cyclo-Oxygenase Inhibition in Cat Antrum Follows Parenteral Administration of Aspirin But Not Salicylate"* by Whittle, et al.	07/05/85	WHITTLE 1046-1051
DTX557				Publication Entitled *"Gastrointestinal Effects of Nonsteroidal Anti-inflammatory Drugs"* by Whittle	10/10/02	WHITTLE 1059-1071
DTX558				Publication Entitled *"Gastrointestinal Toxicity of Nonsteroidal Anti-inflammatory Drugs"* by Wolfe, et al.	06/17/99	WHITTLE 1015-1026
DTX559				Publication Entitled *"Gastroprotective Capability of Exogenous Phosphatidylcholine in Experimentally Induced Chronic Gastric Ulcers in Rats"* by Dunjic, et al.	07/10/92	WHITTLE 0597-602
DTX560				Publication Entitled *"Histological Evidence that Vascular Damage & Mucosal Ulceration Caused by Indomethacin Precede Neutrophil Infiltration in the Rat Gastric Antrum"* by Doble & Bohl	00/00/94	WHITTLE 0594-596
DTX561				Publication *Entitled "Relationship Between the Prevention of Rat Gastric Erosions & the Exhibition of Acid Secretion by Prostaglandins,"* by Whittle	07/27/76	WHITTLE 1052-1058
DTX562				Publication Entitled *"Role of Pepsin in the Development of Indomethacin-Induced Antral Ulceration in the Rat,"* by Gaio, et al.	11/29/94	WHITTLE 0617-622
DTX563				Publication Entitled *"Role of Prostaglandins in the Defense of the Gastric Mucosa,"* by Whittle	00/00/80	WHITTLE 0427-434
DTX564				Search Results for Citations of Gastroenterology Article	00/00/00	WHITTLE 0447-546

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX565				Publication Entitled *"Sodium-Salicylate in Contrast with Acetylsalic Acid Prevents Gastric Antral & Intestinal Ulcers Produced by Indomethacin in the Refed Rat,"* by Ezer	11/25/94	WHITTLE 0603-606
DTX566				Publication Entitled *"Stimulation of Gastric Prostaglandin Synthesis by Refeeding in the Rat,"* Satoh, et al.	04/00/84	WHITTLE 0864-869
DTX567				Publication Entitled *"Stimulation of Gastric Prostaglandin Synthesis by Refeeding in the Rat: Role in Protection of Gastric Mucosa from Damage"* by Satoh, et al.	04/00/84	WHITTLE 1039-1044
DTX568				Study 20637: Explanation of Details: Indomethacin Induced Gastric Lesions	00/00/00	WHITTLE 1121-1123
DTX569				Portion of Takeda's IND Submission	00/00/00	WHITTLE 0257
DTX570				Publication Entitled *"Temporal Relationship Between Cyclooxygenase Inhibition, as Measured by Prostacyclin Biosynthesis, & the Gastrointestinal Damage Induced by Indomethacin in the Rat,"* by Whittle	08/05/80	WHITTLE 0435-439
DTX571				Publication Entitled *"The Differential Roles of Sympathetic Nerve Activity in the Pathogenesis of Antral & Corpus Lesions Induced by Indomethacin in Rats,"* by Kuratani, et al.	07/07/94	WHITTLE 0736-743
DTX572				Publication Entitled *"The Pharmacological Differences & Similarities Between Stress & Ethanol Induced Gastric Mucosal Damage,"* by Cho & Ogle	10/01/92	WHITTLE 0577-586
DTX573				Publication Entitled *"The Role of Acid in the Pathogenesis of Indomethacin-induced Gastric Antral Ulcers in the Rat,"* by Clayton	01/29/96	WHITTLE 0587-593
DTX574				Certified Translation of TAKEDA 040942	07/03/07	WHITTLE 0248-250
DTX575				Certified Translation of TAKEDA 040950	07/03/07	WHITTLE 0251-253
DTX576				Certified Translation of TAKEDA 040957	07/03/07	WHITTLE 0254-256
DTX577				Certified Translation of TAKEDA 436710-733	07/03/07	WHITTLE 0285-333
DTX578				Certified Translation of TAKEDA 040954-956	07/03/07	WHITTLE 0440-446
DTX579				Certified Translation of TAKEDA 638780-784	07/25/07	WHITTLE 1819-1829
DTX580				Certified Translation of TAKEDA 638807-814	07/25/07	WHITTLE 1830-1846
DTX581				Certified Translation of TAKEDA 639114-115	07/25/07	WHITTLE 1847-1851
DTX582				Certified Translation of TAKEDA 639116-117	07/25/07	WHITTLE 1852-1856
DTX583				Certified Translation of TAKEDA 642665-670	07/03/07	WHITTLE 1857-1869
DTX584				Certified Translation of TAKEDA 642671-676	07/03/07	WHITTLE 1870-1882
DTX585				Certified Translation of TAKEDA 642701-706	07/03/07	WHITTLE 1883-1895

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX586				Certified Translation of TAKEDA 642707-711	07/25/07	WHITTLE 1896-1906
DTX587				Certified Translation of TAKEDA 642773-776	07/25/07	WHITTLE 1907-1915
DTX588				Certified Translation of TAKEDA 642777-781	07/25/07	WHITTLE 1916-1926
DTX589				Certified Translation of TAKEDA 642785	07/25/07	WHITTLE 1927-1929
DTX590				Certified Translation of TAKEDA 642786-789	07/25/07	WHITTLE 1930-1938
DTX591				Certified Translation of TAKEDA 649106-113	07/03/07	WHITTLE 1939-1955
DTX592				Certified Translation of TAKEDA 649114-122	07/03/07	WHITTLE 1956-1974
DTX593				Certified Translation of TAKEDA 649123-128	07/03/07	WHITTLE 1975-1987
DTX594				Certified Translation of TAKEDA 649135-140	07/03/07	WHITTLE 1988-2000
DTX595				Publication Entitled *"Antisecretory & Antiulcer Activities of a Novel Proton Pump Inhibitor AG-1749 in Dogs & Rats,"* by Satoh, et al.	11/08/88	TVL 059756-65
DTX596				Publication Entitled *"Antiulcer Effect of Lafutidine on Indomethacin-Induced Gastric Antral Ulcers in Refed Rats,"* by Onodera, et al.	04/02/99	WHITTLE 0844-850
DTX597				Publication Entitled *"The Location of Gastric Ulcer,"* by Or, et al.	01/00/59	WHITTLE 0832-843
DTX598				Certified Translation of Central Research Division Monthly Report August 1980	08/00/80	TAKEDA 040645-648
DTX599				Certified Translation of Central Research Division Monthly Report October 1982	10/00/82	TAKEDA 040778-783
DTX600				Certified Translation of Central Research Division Monthly Report June 1983	06/00/83	TAKEDA 040831-839
DTX601				Certified Translation of Central Research Division Monthly Report July 1983	07/00/83	TAKEDA 040840-848
DTX602				Certified Translation of Central Research Division Monthly Report August 1983	08/00/83	TAKEDA 040849-857
DTX603				Certified Translation of Central Research Division Monthly Report September 1983	09/00/83	TAKEDA 040858-865
DTX604				Certified Translation of Central Research Division Monthly Report December 1983	12/00/83	TAKEDA 040883-890
DTX605				Certified Translation of Central Research Division Monthly Report January 1984	01/00/84	TAKEDA 040891-897
DTX606				Certified Translation of Central Research Division Monthly Report February 1984	02/00/84	TAKEDA 040898-905

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX607				Certified Translation of Central Research Division Monthly Report March 1984	03/00/84	TAKEDA 040906-913
DTX608				Certified Translation of Central Research Division Monthly Report April 1984	04/00/84	TAKEDA 040914-920
DTX609				Certified Translation of Monthly Report Project Theme October 1984	10/00/84	TAKEDA 040965-970
DTX610				Certified Translation of Monthly Report Project Theme November 1984	11/00/84	TAKEDA 040978-985
DTX611				Certified Translation of Monthly Report Project Theme December 1984	12/00/84	TAKEDA 040993-1002
DTX612				Certified Translation of Institute Director's Monthly Report December 1984	12/00/84	TAKEDA 450671-673
DTX613				Certified Translation of The Biological Research Institute Director December 1984	12/00/84	TAKEDA 450674-675
DTX614				Certified Translation of Central Research Division Monthly Report January 1985	01/00/85	TAKEDA 041003-9
DTX615				Certified Translation of Monthly Report Project Theme January 1985	01/00/85	TAKEDA 041010-18
DTX616				Certified Translation of Central Research Division Monthly Report February 1985	02/00/85	TAKEDA 041019-25
DTX617				Certified Translation of Monthly Report Project Theme February 1985	02/00/85	TAKEDA 041026-38
DTX618				Certified Translation of Central Research Division Monthly Report March 1985	03/00/85	TAKEDA 041039-45
DTX619				Certified Translation of Monthly Report Project Theme March 1985	03/00/85	TAKEDA 041046-62
DTX620				Certified Translation of Monthly Report March 1985	03/00/85	TAKEDA 047472-473
DTX621				Certified Translation of Central Research Division Monthly Report April 1985	04/00/85	TAKEDA 041063-69
DTX622				Certified Translation of Monthly Report Project Theme April 1985	04/00/85	TAKEDA 041070-85
DTX623				Certified Translation of Monthly Report April 1985	04/00/85	TAKEDA-047470
DTX624				Certified Translation of Monthly Report April 1985	04/00/85	TAKEDA-047471
DTX625				Certified Translation of Central Research Division Monthly Report May 1985	05/00/85	TAKEDA 041086-91

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX626				Certified Translation of Monthly Report Project Theme May 1985	05/00/85	TAKEDA 041092-109
DTX627				Certified Translation of Monthly Report May 1985	05/00/85	TAKEDA-047468
DTX628				Certified Translation of Monthly Report May 1985	05/00/85	TAKEDA-047469
DTX629				Certified Translation of Monthly Report May 1985	05/00/85	TAKEDA 047602-604
DTX630				Certified Translation of Monthly Report May 1985	05/00/85	TAKEDA-047605
DTX631				Certified Translation of Central Research Division Monthly Report June 1985	06/00/85	TAKEDA 041110-116
DTX632				Certified Translation of Monthly Report Project Theme June 1985	06/00/85	TAKEDA 041117-132
DTX633				Certified Translation of Monthly Report June 1985	06/00/85	TAKEDA-047467
DTX634				Certified Translation of Monthly Report June 1985	06/00/85	TAKEDA 047598-600
DTX635				Certified Translation of Monthly Report Project Theme July 1985	07/00/85	TAKEDA 041140-154
DTX636				Certified Translation of Monthly Report July 1985	07/00/85	TAKEDA 047593-597
DTX637				Certified Translation of Central Research Division Monthly Report August 1985	08/00/85	TAKEDA 041155-160
DTX638				Certified Translation of Monthly Report Project Theme August 1985	08/00/85	TAKEDA 041161-173
DTX639				Certified Translation of Monthly Report August 1985	08/00/85	TAKEDA 047463-464
DTX640				Certified Translation of Monthly Report August 1985	08/00/85	TAKEDA 047589-590
DTX641				Certified Translation of Central Research Division Monthly Report September 1985	09/00/85	TAKEDA 041174-181
DTX642				Certified Translation of Monthly Report Project Theme September 1985	09/00/85	TAKEDA 041182-192
DTX643				Certified Translation of Monthly Report September 1985	09/00/85	TAKEDA 047585-588
DTX644				Certified Translation of Central Research Division Monthly Report October 1985	10/00/85	TAKEDA 041193-200
DTX645				Certified Translation of Monthly Report Project Theme October 1985	10/00/85	TAKEDA 041201-209
DTX646				Certified Translation of Monthly Report October 1985	10/00/85	TAKEDA 047459-460
DTX647				Certified Translation of Central Research Division Monthly Report November 1985	11/00/85	TAKEDA 041210-217
DTX648				Certified Translation of Monthly Report November 1985	11/00/85	TAKEDA 047457-458
DTX649				Certified Translation of Monthly Report November 1985	11/00/85	TAKEDA 047579-581
DTX650				Certified Translation of Monthly Report December 1985	12/00/85	TAKEDA 047573-575

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX651				Certified Translation of Monthly Report January 1986	01/00/86	TAKEDA 047566-569
DTX652				Certified Translation of Monthly Report January 1986	01/00/86	TAKEDA 047570-572
DTX653				Certified Translation of Monthly Report February 1986	02/00/86	TAKEDA 451162-164
DTX654				Certified Translation of Monthly Report February 1986	02/00/86	TAKEDA 047559-562
DTX655				Certified Translation of Monthly Report February 1986	02/00/86	TAKEDA 047563-565
DTX656				Certified Translation of Monthly Report March 1986	03/00/86	TAKEDA 047553-555
DTX657				Certified Translation of Monthly Report March 1986	03/00/86	TAKEDA 047556-557
DTX658				Certified Translation of Monthly Report April 1986	04/00/86	TAKEDA 047549-550
DTX659				Certified Translation of Monthly Report April 1986	04/00/86	TAKEDA 047551-552
DTX660				Certified Translation of Monthly Report May 1986	05/00/86	TAKEDA 047545-547
DTX661				Certified Translation of Monthly Report May 1986	05/00/86	TAKEDA-047548
DTX662				Certified Translation of Central Research Division Monthly Report June 1986	06/00/86	TAKEDA-451589
DTX663				Certified Translation of Monthly Report June 1986	06/00/86	TAKEDA-451600
DTX664				Certified Translation of Project Theme Monthly Report June 1986	06/00/86	TAKEDA-451659
DTX665				Certified Translation of Monthly Report June 1986	06/00/86	TAKEDA 451661-666
DTX666				Certified Translation of Monthly Report June 1986	06/00/86	TAKEDA 047540-542
DTX667				Certified Translation of Monthly Report June 1986	06/00/86	TAKEDA 047543-544
DTX668				Certified Translation of Project Theme Monthly Report July 1986	07/00/86	TAKEDA-451648
DTX669				Certified Translation of Monthly Report July 1986	07/00/86	TAKEDA-047539
DTX670				Certified Translation of Monthly Report August 1986	08/00/86	TAKEDA-451633
DTX671				Certified Translation of Central Research Division Monthly Report August 1986	08/00/86	TAKEDA-451614
DTX672				Certified Translation of Project Theme Monthly Report August 1986	08/00/86	TAKEDA-451636
DTX673				Certified Translation of Monthly Report August 1986	08/00/86	TAKEDA-451638
DTX674				Certified Translation of Monthly Report August 1986	08/00/86	TAKEDA 047535-536
DTX675				Certified Translation of Monthly Report August 1986	08/00/86	TAKEDA 047537-538
DTX676				Certified Translation of Monthly Report September 1986	09/00/86	TAKEDA 047530-532
DTX677				Certified Translation of Monthly Report September 1986	09/00/86	TAKEDA 047533-534
DTX678				Certified Translation of Monthly Report October 1986	10/00/86	TAKEDA 047525-527
DTX679				Certified Translation of Monthly Report October 1986	10/00/86	TAKEDA 047528-529
DTX680				Certified Translation of Monthly Report November 1986	11/00/86	TAKEDA 047520-522

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX681				Certified Translation of Monthly Report November 1986	11/00/86	TAKEDA 047523-524
DTX682				Certified Translation of Monthly Report December 1986	12/00/86	TAKEDA 047516-517
DTX683				Certified Translation of Monthly Report December 1986	12/00/86	TAKEDA 047518-519
DTX684				Certified Translation of Monthly Report January 1987	01/00/87	TAKEDA 047514-515
DTX685				Certified Translation of Monthly Report February 1987	02/00/87	TAKEDA 047512-513
DTX686				Certified Translation of Monthly Report March 1987	03/00/87	TAKEDA 047510-511
DTX687				Certified Translation of Monthly Report April 1987	04/00/87	TAKEDA 047508-509
DTX688				Certified Translation of Monthly Report May 1987	05/00/87	TAKEDA 047506-507
DTX689				Certified Translation of Monthly Report June 1987	06/00/87	TAKEDA 047504-505
DTX690				Certified Translation of Monthly Report July 1987	07/00/87	TAKEDA 047498-503
DTX691				Certified Translation of Monthly Operations Report February 1990	02/00/90	TAKEDA 448008-14
DTX692				Certified Translation of Monthly Report by Chemical Research Institute Director 5/15/91	05/00/91	TAKEDA 449291-292
DTX693				Certified Translation of Monthly Report Project Theme June 1991	06/00/91	TAKEDA 452146
DTX694				Certified Translation of Monthly Report June 1991	06/00/91	TAKEDA 452148
DTX695				Certified Translation of Monthly Report May 1991	05/00/91	TAKEDA 452149-150
DTX696				Certified Translation of Monthly Report June 1991	06/00/91	TAKEDA 452151-159
DTX697				Certified Translation of Monthly Report May 1991	05/00/91	TAKEDA 452207
DTX698				Certified Translation of Monthly Report August 1991	08/00/91	TAKEDA 452241-242
DTX699				Certified Translation of Monthly Report August 1991	08/00/91	TAKEDA 452247
DTX700				Certified Translation of Monthly Report January 1992	01/00/92	TAKEDA 437888-984
DTX701				Certified Translation of Project Theme Monthly Report April 1992	04/00/92	TAKEDA 452419
DTX702				Certified Translation of Monthly Report April 1992	04/00/92	TAKEDA 452424
DTX703				Certified Translation of TAKEDA 044462	00/00/00	TAKEDA 044462
DTX704				Certified Translation of Research Meeting Document	08/24/84	TAKEDA 044211-212
DTX705				Certified Translation of Planning & Development Head Office Interim Research Meeting (131ST) Document - AG-1749	12/00/84	TAKEDA 044306-330
DTX706				Certified Translation of Planning & Development Head Office Interim Research Meeting (125th) Document - AG-1749	00/00/00	TAKEDA 044367-407
DTX707				Certified Translation of Study on Development of AG-1740 Preparation (Status Report)	02/24/86	TAKEDA 047773-777
DTX708				Certified Translation of Evaluation of Omeprazole Preparation	07/22/86	TAKEDA 048568-569

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX709				Certified Translation of Background of Discovery of Lansoprazole & Device for the Preparation Thereof	00/00/00	TAKEDA 353080-087
DTX710				Certified Translation of Lansoprazole & Takepron Capsules – Instructions from the First Investigative Committee on New Medical Products – Response Document	02/10/92	TAKEDA 480342-682
DTX711				Certified Translation of letter from K. Nakatsuka to H. Shinba	07/11/97	TAKEDA 396847-854
DTX712				Certified Translation of Japanese Unexamined Patent Application No. S61-50978	03/13/86	TAKEDA 018270-276
DTX713				Letter from K. Kitazawa to J. Seely	12/13/94	TAKEDA 554515
DTX714				Takeda Pharmaceutical Company Ltd.'s Initial Disclosure Pursuant to Rule 26(a)(1) with Notice of Service	03/06/06	
DTX715				TAP Pharmaceutical Products Inc.'s Initial Disclosure Pursuant to Rule 26(a)(1) with Notice of Service	03/06/06	
DTX716				Teva Pharmaceuticals USA, Inc.'s Responses & Objections to TAP Pharmaceutical Products, Inc.'s 1st Set of Interrogatories	04/10/06	
DTX717				Teva Pharmaceuticals USA, Inc.'s Responses to Plaintiffs' 1st Set of Requests for the Production of Documents & Things	04/10/06	
DTX718				Takeda Pharmaceutical Company, Ltd.'s Responses & Objections to Teva Pharmaceuticals USA, Inc.'s 1st Set of Requests for the Production of Documents & Things (Nos. 1-47) with Notice of Service	04/17/06	
DTX719				TAP Pharmaceutical Products Inc.'s Responses to Teva Pharmaceuticals USA, Inc.'s 1st Set of Request for the Production of Documents & Things	04/17/06	
DTX720				Teva Pharmaceutical Industries Ltd.'s Responses & Objections To Interrogatory Nos. 7 & 8 of TAP Pharmaceutical Products, Inc.'s 1st Set of Interrogatories	08/11/06	
DTX721				Teva Pharmaceutical Industries Ltd.'s Responses To Request Nos. 40 & 42 of Plaintiff's 1st Set of Requests For The Production of Documents & Things	08/11/06	
DTX722				Teva Pharmaceuticals USA, Inc.'s Suppl. Responses to Interrogatory Nos. 7 & 8 of TAP Pharmaceutical Products, Inc.'s 1st Set of Interrogatories	08/11/06	
DTX723				Takeda Pharmaceutical Company, Ltd.'s Responses & Objections to Teva Pharmaceuticals USA, Inc.'s 1st Set of Interrogatories (Nos. 1-9)	10/23/06	

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX724				Takeda Pharmaceutical Company, Ltd.'s. Suppl. Responses & Objections to Teva Pharmaceuticals USA, Inc.'s 1st Set of Interrogatories (Nos. 1-3 & 8)	12/11/06	
DTX725				TAP Pharmaceutical Products, Inc.'s Responses & Objections to Teva Pharmaceuticals Industries, Ltd.'s 1st Set of Interrogatories (Nos. 1-8)	12/11/06	
DTX726				Teva Pharmaceuticals USA, Inc.'s & Teva Pharmaceutical Industries Ltd.'s Suppl. Responses & Objections to TAP Pharmaceutical Products, Inc.'s Interrogatory No. 3	12/12/06	
DTX727				Teva Pharmaceutical USA, Inc. & Teva Pharmaceutical Industries Ltd.'s Responses to Takeda's 2nd Set of Requests for the Production of Documents & Things (Nos. 43-45)	02/20/07	
DTX728				Takeda Pharmaceutical Company Ltd. & TAP Pharmaceutical Products Inc.'s Responses & Objections to Teva Pharmaceutical Industries, Ltd.'s 2nd Set of Interrogatories to Takeda Pharmaceutical Company Ltd. (No. 10) & to TAP Pharmaceuticals USA, Inc. (No. 9)	02/28/07	
DTX729				Takeda Pharmaceutical Company Ltd. & TAP Pharmaceutical Products Inc.'s 2nd Set of Suppl. Responses & Objections to Teva Pharmaceutical USA, Inc.'s 1st Set of Interrogatories (Nos. 1-2)	03/22/07	
DTX730				Takeda Pharmaceutical Company, Ltd.'s & TAP Pharmaceutical Products, Inc.'s Responses & Objections to Teva Pharmaceuticals USA, Inc.'s 1st Set of Requests for Admission to Plaintiffs	04/12/07	
DTX731				Takeda Pharmaceutical Company, Ltd. & TAP Pharmaceutical Products, Inc.'s Responses & Objections to Teva Pharmaceutical Industries, Ltd.'s 3rd Set of Interrogatories to Takeda (Nos. 11-16) & TAP (Nos. 10-15)	04/12/07	
DTX732				Teva Pharmaceuticals USA, Inc.'s & Teva Pharmaceutical Industries Ltd's Responses to Takeda Pharmaceutical Company, Ltd's 1st Set of Requests for Admission (Nos. 1-3)	07/18/07	
DTX733				Excerpts from S. DiCapua Deposition	02/07/07	TEVA'S OPENING CC BRIEF EX. 5
DTX734				Proposed Claim Construction of the Disputed Terms of Claims 1 & 2 of U.S. Patent 5,045,321	00/00/00	TEVA'S OPENING CC BRIEF EX. 2

DEF EX. NO.	OFFERED	ADMT	WITNESS	EX. DESCRIPTION	DATE	BATES NO.
DTX735				U.S. Patent Application No. 07/014,303 – Amendment for Extension of Time Petition	02/13/87	HAM 3514-525
DTX736				U.S. Patent Application No. 07/014,303 – Amendment Submitted Under 37 CFR 1.115	11/02/88	TAKEDA 739670-739680
DTX737				Publication Entitled: *"U.S. Pharmacopeia: About USP – An Overview"*	09/10/07	TEVA'S OPENING CC BRIEF EX. 11
DTX738				U.S. Patent Application No. 07/014,303 – Appeal Brief	02/13/87	TAKEDA 739750-739771
DTX739				U.S. Patent Application No. 07/014,303 – Reply Brief to 3rd Suppl. Examiner's Answer	09/28/90	TAKEDA 739830-739837
DTX740				U.S. Patent Application No. 07/014,303 – Suppl. Amendment Submitted Under 37 CFR 1.115	01/31/89	TAKEDA 739683-739690
DTX741				U.S. Patent Application 07/04,303 - 2nd Reply Brief	05/21/90	TAKEDA 739811-739815
DTX742				ANDA #77-255 – Formula Composition	07/00/04	TVL 006617-6618
DTX743				Lab Notebook 2332	00/00/00	TAKEDA 642642-642824
DTX744				FDA Meeting Minutes from 10/21	11/5/87	TAP 0274540-274543
DTX745				Letter from J. Seely to K. Kitazawa	05/13/94	TAKEDA 546936
DTX746				FDA Meeting Minutes from August 9, 1990	08/09/90	TAP 0227323-227325
DTX747				Letter from J. Seely to K. Kitazawa	04/20/95	TAP 194492-194493
DTX748				TAP Memorandum from J. Wargel to D. Chin, et al.	09/18/89	TAP 274559-274564
DTX749				Publication Entitled *"Webster's New Universal Unabridged Dictionary"*	00/00/83	TEVA'S OPENING CC BRIEF EX. 7
DTX750				Proposed Claim Construction of the Disputed Terms of Claims 1 & 10 of U.S. Patent 4,628,098	00/00/00	PLAINTIFF'S OPENING CC BRIEF EX. 3
DTX751				Subpoena in a Civil Case served on AstraZeneca Pharmaceuticals LP	12/05/06	
DTX752				Subpoena in a Civil Case served on White & Case LLP	12/05/06	
DTX753				Deposition of H. Iwata	03/01/94	FOLEY 0001-149
DTX754				Deposition of H. Iwata	03/02/94	FOLEY 0150-333
DTX755				Takeda Privilege Logs		
DTX756				Teva Privilege Logs		

EXHIBIT 7

EXHIBIT 7

PLAINTIFFS' WITNESSES THAT MAY APPEAR AT TRIAL

Plaintiffs may call one or more of the following witnesses:

1. Gordon Amidon, Ph.D., Professor of Pharmacy and Pharmaceutical Sciences, University of Michigan College of Pharmacy

2. David Bugay, Ph.D., Managing Director, Aptuit Consulting, West Lafayette, Indiana

3. Stephen Byrn, Ph.D., Professor of Medicinal Chemistry and Head of the Department of Industrial and Physical Pharmacy, Purdue University

4. Doug Cole, Vice President, Sales, TAP Pharmaceutical Products Inc.

5. M. Brian Fennerty, M.D., Professor of Medicine and Section Chief of Gastroenterology, Department of Internal Medicine, Oregon Health and Science University

6. Jonathan Kaunitz, M.D., Professor of Medicine, David Geffen School of Medicine, UCLA

7. Keiji Kubo, Ph.D., Research Manager, Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division Takeda Pharmaceutical Company Limited

8. Christopher Lipinski, Ph.D., Scientific Advisor, Melior Discovery, Inc., formerly Senior Research Fellow, Pfizer Global Research and Development (retired)

9. Tetsuro Tabata, Ph.D., Research Manager, Pharmaceutical Technology R&D Laboratories, CMC Center Pharmaceutical Production Division, Takeda Pharmaceutical Company Limited

10. Brendan Whittle, Ph.D., Professor of Applied Pharmacology, St. Bartholomew's and The Royal London School of Medicine and Dentistry, University of London; Director, William Harvey Research Limited

EXHIBIT 8

EXHIBIT 8

PLAINTIFFS' DESIGNATIONS FROM THE DEPOSITION OF AKIRA NOHARA

Akira Nohara			
February 1, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
5	21	6	17
8	9	8	11
8	13	8	15
9	22	9	23
10	11	10	15
14	8	14	12
16	23	17	1
17	20	17	22
18	2	18	4
24	24	25	3
26	24	27	19
29	20	29	24
31	9	31	11
31	17	31	18
31	20	31	23
33	2	33	11
47	19	48	1
48	4	48	5
48	14	48	16
48	19	49	3
58	2	58	8
58	13	58	17
58	23	59	6
60	4	60	6
60	9	60	13
64	10	64	13
64	16	64	17
66	13	66	23
68	14	68	20
77	21	77	23
78	2	78	6
78	11	78	13

Akira Nohara			
February 1, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
79	3	79	8
79	19	79	20
80	3	80	10
80	12	80	18
80	20	80	21
80	23	81	6
98	19	98	21
99	4	99	20

PLAINTIFFS' DESIGNATIONS FROM
THE DEPOSITION OF YOSHITAKA MAKI

Yoshitaka Maki			
January 30, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
8	3	8	7
8	15	8	20
9	1	9	2
9	11	9	17
10	22	10	24
46	4	46	13
46	24	47	1
47	21	47	23
48	2	48	3
48	5	48	8
48	13	48	17
49	25	50	3
50	5	50	9
50	18	50	22
52	24	52	25
53	19	54	1
76	5	76	9
77	3	77	8
78	6	78	9

Yoshitaka Maki			
January 30, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
78	13	78	13
112	11	112	17
114	18	115	1
115	15	115	18
115	23	115	25
116	6	116	10
116	14	116	15
116	17	116	18
117	1	117	5
117	7	117	8
117	21	117	25

PLAINTIFFS' DESIGNATIONS FROM THE DEPOSITION OF HIROSHI SATOH

Hiroshi Satoh			
February 27, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
15	13	15	16
16	22	17	5
17	20	17	24
18	10	18	20
20	21	21	24
25	8	25	13
25	19	26	7
26	20	27	4
30	16	30	20
31	2	31	21
31	25	32	3

Hiroshi Satoh			
February 27, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
32	5	32	7
34	21	35	25
40	17	41	14
41	21	41	23
42	3	42	5
42	9	42	20
44	10	44	16
45	1	45	2
45	13	45	19
46	21	46	24
47	16	47	24
52	21	52	23
53	4	53	7
53	18	53	21
53	25	55	3
55	7	55	13
55	16	55	24
56	4	56	6
59	15	59	16
60	19	61	20
61	23	62	7
63	24	64	2
64	25	65	9
74	5	74	18
78	22	79	2
79	6	79	7
79	9	79	11
79	13	79	14

Hiroshi Satoh			
February 27, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
79	16	79	18
80	8	80	24
82	15	82	20
84	15	84	19
87	20	88	8
88	14	88	19
89	1	89	18
90	20	91	9
91	12	91	14
92	6	92	23
93	5	93	6
93	10	93	19
93	23	94	4
94	8	94	19
95	7	95	21
96	12	96	15
96	19	96	25
97	8	97	11
97	13	97	13
97	18	97	19
101	12	101	15
101	20	101	24

PLAINTIFFS' DESIGNATIONS FROM
THE DEPOSITION OF SIMONA DI CAPUA

Simona Di Capua			
February 7, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
9	24	9	25
10	7	10	8
23	18	24	9
29	22	30	9
54	25	55	12
60	25	61	8
64	7	64	23
67	11	67	21
72	18	73	12
87	4	87	11
87	16	87	16
87	19	87	22
87	25	87	25
89	18	89	25
91	23	92	10
101	14	101	22
101	24	102	21
102	23	103	5
107	2	107	8
108	10	108	13
108	15	108	24
109	11	109	16
109	18	110	10
110	13	110	23

Simona Di Capua			
February 7, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
110	25	111	7
111	14	111	19
140	2	140	5
140	23	141	7
150	6	150	11
150	16	150	23

PLAINTIFFS' DESIGNATIONS FROM THE DEPOSITION OF DAVID COLE

David Cole			
September 4, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
9	5	9	7
9	19	9	20
21	4	21	9
27	6	27	14
27	16	27	21
28	13	28	14
53	10	53	13
53	16	53	19
54	13	54	15
55	4	55	7
56	9	56	13
63	10	63	11

David Cole			
September 4, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
63	14	63	14
64	4	64	7
64	9	64	16
64	20	65	13
65	16	65	24
66	3	66	8
69	4	69	10
69	16	69	20
69	22	69	22
70	9	70	11
70	14	70	19
123	9	123	23
124	20	124	22
125	11	125	17
148	20	148	22
149	5	149	11
149	13	149	13

PLAINTIFFS' DESIGNATIONS FROM
THE DEPOSITION OF SHINICHIRO HIRAI

Shinichiro Hirai			
February 2, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
5	11	5	23
37	19	37	23

Shinichiro Hirai			
February 2, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
38	4	38	8
78	17	78	21
79	19	79	22
80	14	80	19

PLAINTIFFS' DESIGNATIONS FROM
THE DEPOSITION OF PHILIP ERICKSON

Philip Erickson			
February 21, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
4	9	4	13
10	8	10	23
29	2	29	15
34	18	34	22
38	8	38	14

EXHIBIT 8

PLAINTIFFS' COUNTER DESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF LYLE BROSTROM

Lyle Brostrom			
August 28, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
8	22	9	25
11	24	12	10
41	6	41	10
55	10	56	7
56	10	56	10

PLAINTIFFS' COUNTER DESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF SHINICHIRO HIRAI

Shinichiro Hirai			
February 2, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
57	6	57	12
57	18	57	18

PLAINTIFFS' COUNTER DESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE 12/18/06 DEPOSITION OF TADAAKI KITAO

Tadaaki Kitao			
December 18, 2006 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
60	7	60	8
103	7	103	10

PLAINTIFFS' COUNTER DESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE 3/23/07 DEPOSITION OF TADAAKI KITAO

Tadaaki Kitao			
March 23, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
29	21	30	3
30	13	31	17
40	24	40	25
45	20	46	9
46	24	47	20
47	24	48	4
52	8	52	14
52	22	53	5
55	12	56	11
56	22	56	25
66	5	67	15
71	14	72	3
80	11	80	25
85	9	85	18
85	22	86	9
86	19	86	24
92	9	92	22

Tadaaki Kitao			
March 23, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
117	4	118	8
121	19	122	6
124	21	125	4
125	14	128	3

PLAINTIFFS' COUNTER DESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF TATSUHIKO KANEKO

Tatsuhiko Kaneko			
February 28, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
5	23	5	25
14	5	14	12
15	18	16	1
16	22	17	7
62	21	63	6
66	17	67	20
73	13	73	21
77	20	77	22
78	9	79	1
84	2	84	3
95	13	95	13
96	20	96	24

PLAINTIFFS' COUNTER DESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF YOSHITAKA MAKI

Yoshitaka Maki			
January 30, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
41	13	41	17
41	21	42	2
42	4	42	7
42	9	42	12
42	15	42	17
61	15	61	18
62	1	62	4
67	9	67	16
69	12	69	14
70	15	70	16

PLAINTIFFS' COUNTER DESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF TADASHI MAKINO

Tadashi Makino			
January 31, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
87	17	88	1

PLAINTIFFS' COUNTER DESIGNATIONS FROM THE DEPOSITION OF STEPHEN MAEBIUS

Stephen Maebius			
May 15, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
35	5	35	6
35	8	35	9

PLAINTIFFS' COUNTERDESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF DOUG MUELLER

Doug Mueller			
April 12, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
14	9	14	12
34	6	34	9
48	2	48	5
53	6	53	8
56	1	56	23

PLAINTIFFS' COUNTERDESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF AKIRA NOHARA

Akira Nohara			
February 1, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
43	18	43	24
44	5	44	6

Akira Nohara			
February 1, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
45	19	45	22
45	25	45	25

PLAINTIFFS' COUNTERDESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF KATUSAKI ODA

Katusaki Oda			
February 26, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
32	11	32	13
32	18	32	18
33	3	33	21
34	9	34	25
41	14	41	17
42	13	42	24
43	24	44	2
44	20	44	20
44	24	45	16
45	19	45	20
46	11	46	15
52	11	53	14
64	8	64	17
64	24	64	24
65	1	65	9
65	14	65	20

Katusaki Oda			
February 26, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
65	22	65	22
65	24	66	2
66	5	66	9
69	22	70	8
70	14	71	15

PLAINTIFFS' COUNTERDESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF JOHN SEELY

John Seely			
April 18, 2006 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
6	2	6	6
23	6	25	13
29	7	30	17
33	8	33	12
36	13	38	4

PLAINTIFFS' COUNTERDESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF DEAN SUNDBERG

Dean Sundberg			
April 9, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
9	4	9	6
15	10	15	11
32	15	33	19
73	8	73	22
74	5	74	9
76	9	76	17
77	11	77	21
79	4	79	10
80	2	80	12
84	1	84	24
89	3	89	12
112	12	113	12
128	1	128	5

PLAINTIFFS' COUNTERDESIGNATIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF HAROLD WEGNER

Harold Wegner			
August 15, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
28	2	28	9

PLAINTIFFS' OBJECTIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITION OF PAUL FACKLER

Plaintiffs object to Defendants' designations of Paul Fackler. Mr. Fackler is a current employee of Teva USA and is within Defendants' control. Moreover, the witness is within 100 miles of the Court and could be brought by Teva to testify.

PLAINTIFFS' OBJECTIONS TO DEFENDANTS' DESIGNATIONS FROM THE DEPOSITIONS OF JAMIE BOULET, HENRY JACOBY AND GAO DONG

Plaintiffs object to Teva's designation of the depositions of its consultants hired for the purpose of this litigation, including Jamie Boulet, Henry Jacoby and Gao Dong. These witnesses are within Teva's control. Moreover, these "experts" were not identified as required under Fed. R. Civ. P. 26(a)(2)(C) and did not submit expert reports. In addition, all three witnesses are within 100 miles of the Delaware Court and could be brought by Teva to testify.

EXHIBIT 9

EXHIBIT 9

DEFENDANTS' WITNESSES THAT MAY APPEAR AT TRIAL

Defendants may call one or more of the following witnesses:

1. George Lenz, Ph.D., MBA, President, GRLEN R&D Associates, Andover, Massachusetts

2. Esam Dajani, Ph.D., FACG, Founder and President, IDDC Corporation, Long Grove, Illinois; Adjunct Professor of Medicine, Loyola University, Chicago

3. Meyer Solny, M.D., Gastroenterologist and Internist (private practice); Assistant Attending Physician, Department of Medicine, Division of Gastroenterology and Hepatology, New York Presbyterian Hospital; Clinical Instructor in Medicine, Weill Cornell College of Medicine

4. Robert Hirsch, Ph.D., Professor, Department of Epidemiology and Biostatistics, School of Public Health and Health Services, and Adjunct Professor, Department of Statistics, George Washington University

5. Walter Chambliss, Ph.D., Professor of Pharmaceutics, Director of Technology Management, and Research Professor for the National Center for National Products Research, University of Mississippi

6. Gerald Meyer, Ph.D., Professor of Chemistry and Materials Science and Engineering, Johns Hopkins University

7. Andrew Hirt, President and Senior Scientist, Materials Research Laboratories, Inc. ("MRL"), Struthers, Ohio

8. Walter Vandaele, Ph.D., Managing Director, Pharmaceutical/Biotech Global Practice, LECG, LLC, Washington, D.C.

9. William Lumma, Senior Scientist, Medicinal Chemistry Department, Merck & Co., Inc. (retired)

10. Limor Ari Pardo, Teva

11. Each of the witnesses identified by Plaintiffs in Exhibit 7.

EXHIBIT 10

EXHIBIT 10

DEFENDANTS' DEPOSITION DESIGNATIONS
FOR WITNESSES THAT WILL NOT TESTIFY AT TRIAL

Tadaaki Kitao			
December 18, 2006 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
3	8	3	13
3	18	3	20
4	7	6	4
7	18	8	6
8	15	9	22
10	13	11	17
12	14	12	17
13	3	13	5
13	11	13	25
14	5	14	14
14	18	14	23
16	2	16	9
18	2	18	7
18	21	19	20
21	14	22	8
22	17	24	9
26	3	27	3
29	3	29	20
30	3	34	13
34	20	34	20
35	23	36	11
37	12	38	18
39	18	40	7
42	18	44	15
45	3	45	19
48	5	50	25
51	8	51	12
52	6	53	3
53	10	54	2
54	12	55	18
57	15	58	20

Tadaaki Kitao			
December 18, 2006 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
59	6	60	6
60	17	61	17
62	3	63	3
63	19	64	11
64	25	65	19
67	2	67	25
68	21	70	12
70	25	71	16
72	25	74	6
74	14	75	25
76	13	77	3
77	21	79	11
80	9	82	8
82	23	83	10
84	8	84	12
85	21	87	5
90	22	91	2
92	13	93	16
95	16	96	2
99	21	101	19
102	10	103	6
107	5	107	18
110	12	111	9
111	13	111	18
112	10	114	9
114	23	115	16
117	6	118	16
120	15	121	10
122	25	123	8
123	17	124	8
126	22	127	19
128	5	129	18
132	5	135	2
136	9	136	15
137	10	139	13
139	22	140	5

Tadaaki Kitao			
December 18, 2006 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
140	21	141	8
141	22	143	6
145	10	146	22

Tadaaki Kitao			
March 23, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
4	23	5	7
5	18	6	20
8	13	10	16
12	3	25	22
26	8	27	19
28	21	29	20
34	6	39	23
41	1	45	3
48	9	52	7
54	6	55	11
57	1	57	11
62	19	66	2
67	18	71	13
72	4	75	8
75	24	80	10
81	1	84	2
86	25	88	7
89	6	92	8
93	21	105	10
105	22	108	14
110	15	111	10
111	15	113	21
114	10	115	21

Tadaaki Kitao			
March 23, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
116	18	117	3
118	9	121	18
122	20	124	12
128	20	130	7
132	10	132	16
133	14	134	21

Yoshitaka Maki			
January 30, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
7	11	7	13
7	17	7	18
8	3	9	17
10	12	10	25
11	3	11	23
12	3	15	6
15	16	15	18
17	3	17	25
18	11	20	2
21	6	22	2
22	19	22	22
23	23	24	12
24	22	25	17
26	18	27	25
28	3	28	22
29	18	29	25
30	10	31	25
33	1	33	5
33	13	33	15
33	22	33	25

Yoshitaka Maki			
January 30, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
36	3	36	16
37	14	37	21
38	11	39	21
40	3	41	12
44	7	45	19
52	12	52	16
55	25	56	8
62	17	63	12
63	22	64	25
65	25	66	23
67	1	67	1
67	17	67	20
69	5	69	10
71	5	71	20
75	14	76	9
76	23	77	8
78	6	81	25
83	17	84	6
86	2	87	10
87	22	88	14
91	9	92	23
94	17	95	6
96	13	102	18
105	8	110	18
112	11	114	9
115	23	117	25

Tadashi Makino			
January 31, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
8	22	13	25
16	19	17	4
18	1	18	11
19	22	20	17
21	1	24	24
26	22	31	2
31	22	37	15
40	17	44	24
45	19	48	8
49	12	49	17
51	15	54	14
57	12	58	4
60	11	66	9
67	2	69	23
70	24	75	24
77	20	80	18
80	23	84	22
85	17	87	8
88	16	89	8
94	16	95	19

Akira Nohara			
February 1, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
5	21	6	1
6	15	6	23
7	3	8	19
9	10	9	23
10	5	10	24
12	10	17	6

Akira Nohara			
February 1, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
17	16	19	8
20	12	22	15
22	24	24	22
26	24	28	9
28	18	29	24
33	2	33	6
33	12	33	18
39	10	40	3
42	12	43	17
46	1	49	3
50	25	52	16
53	7	53	12
53	20	57	25
58	2	60	13
63	16	64	2
65	4	65	17
66	13	68	2
77	21	80	2
80	20	81	6
81	21	83	15
88	12	98	11
98	19	100	12
103	22	104	21
105	4	105	19

Shin-ichiro Hirai			
February 2, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
9	13	10	21
11	9	12	3
12	12	14	19
17	9	21	10
22	9	27	11
28	23	43	19
44	5	56	13
58	18	60	19
61	8	61	17
61	23	66	21
68	16	68	24
70	7	72	11
73	24	77	20
78	16	81	10

Katsuaki Oda			
February 26, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
6	9	8	17
9	6	9	21
11	15	12	15
15	20	19	1
19	8	20	1
20	24	21	10
25	8	26	3
27	14	27	22
29	6	31	20
33	23	34	6
35	11	39	3
43	6	43	23

Katsuaki Oda			
February 26, 2007 (Takeda/TAP v. Teva)			
FROM		**TO**	
Page	**Line**	**Page**	**Line**
48	7	48	9
51	23	52	10
53	15	54	3
60	11	61	22
62	5	62	18
66	11	67	9
67	22	68	25
70	14	71	15

Hiroshi Satoh			
February 27, 2007 (Takeda/TAP v. Teva)			
FROM		**TO**	
Page	**Line**	**Page**	**Line**
6	1	10	12
14	16	15	16
15	25	22	1
22	17	23	7
31	1	35	25
42	3	42	5
42	10	43	10
44	10	45	19
46	21	49	8
51	5	51	10
51	13	52	6
52	11	52	23
53	3	53	9
53	18	54	15
56	11	56	15
56	18	58	7
70	2	71	21
74	5	74	18

Hiroshi Satoh			
February 27, 2007 (Takeda/TAP v. Teva)			
FROM		**TO**	
Page	**Line**	**Page**	**Line**
76	24	77	6
78	22	81	18
81	21	83	14
85	7	85	13
92	17	92	25
93	23	97	11
97	22	101	24

Tatsuhiko Kaneko			
February 28, 2007 (Takeda/TAP v. Teva)			
FROM		**TO**	
Page	**Line**	**Page**	**Line**
10	1	10	7
11	25	12	6
13	21	14	4
14	18	14	22
17	8	17	19
29	2	29	6
52	7	52	18
56	9	56	17
65	9	66	16
70	25	73	11
77	1	77	18
84	2	84	14
86	4	86	6
93	9	93	18
93	23	94	18
95	6	95	12
97	19	97	25
98	9	100	3

Paul Fackler			
March 26, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
7	15	8	13
16	2	16	9
18	5	18	25
33	5	33	23
57	8	58	20
59	24	61	20
69	24	70	17
72	19	73	7
76	8	76	22
78	13	86	6
162	3	162	16

Dean Sundberg			
April 9, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
5	2	5	16
8	4	8	6
8	15	9	3
13	1	13	13
14	12	15	9
15	12	15	16
16	19	16	21
18	4	19	17
20	13	22	10
22	24	24	12
27	3	27	24
31	11	32	14
37	2	37	19
56	23	57	10

Dean Sundberg			
April 9, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
57	18	58	24
60	14	60	18
62	5	62	12
66	14	67	6
67	10	67	12
68	7	68	11
69	1	70	8
70	13	72	22
76	18	77	10
78	4	78	22
79	14	80	1
83	2	83	21
86	7	86	15
87	2	88	3
89	13	89	18
91	6	93	8
93	17	94	4
95	11	99	2
104	10	107	19
108	15	109	6
109	22	110	13
113	13	116	8
117	21	119	5
120	3	120	20
122	20	126	1
128	6	129	10
131	5	131	11

Douglas Mueller			
April 12, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
12	20	14	1
14	13	15	23
18	7	28	4
31	3	31	19
32	18	34	5
37	6	48	1
49	17	52	19
53	16	55	24
59	12	59	23

John Seely			
April 18, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
9	23	11	12
17	10	17	13
17	24	18	24
25	14	27	5
30	18	31	9
47	4	56	24
87	13	88	7

Harold Wegner			
May 15, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
12	6	13	7
25	2	28	1
34	21	37	22
40	5	45	13
74	3	79	12

Stephen Maebius			
May 15, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
7	15	8	1
8	13	8	20
9	5	9	20
10	8	11	14
13	8	13	11
23	9	23	15
23	19	24	9
25	6	25	11
25	15	26	12
26	14	26	23
28	8	28	19
30	20	31	12
33	18	33	21
34	1	34	8
34	12	35	4
43	4	43	13
43	19	43	20
44	12	44	19
45	6	46	6
50	10	50	13
50	16	50	23

Stephen Maebius			
May 15, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
51	3	51	5
51	7	51	15
51	18	52	1

Jamie Boulet			
August 14, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
7	16	12	5
13	8	13	16
14	16	15	10
16	4	17	2
18	14	20	11
22	8	22	24
23	13	23	19
27	19	28	4
28	10	29	11
30	18	32	2
32	20	32	22
34	18	37	18
38	3	40	17
42	21	44	4
45	10	45	15
47	4	47	8
47	17	47	19
48	25	49	14
53	17	54	14
56	4	56	25
60	12	60	19
63	4	63	14
64	11	67	5

67	12	67	18
68	12	73	7
74	14	74	18
74	24	75	17
77	5	77	21
78	2	78	25
79	7	80	6
81	1	82	11
83	1	83	5
83	25	84	19
88	14	91	4
92	4	92	8
93	7	93	13
96	3	98	25
99	22	103	7
105	5	108	7

Henry Jacoby			
August 14, 2007 (Takeda/TAP v. Teva)			
FROM		**TO**	
Page	**Line**	**Page**	**Line**
7	14	14	14
16	3	20	14
22	18	24	20
25	5	25	16
26	19	27	17
32	19	34	21
35	17	36	24
43	5	45	4
49	12	49	19
50	12	50	21
57	13	58	21
65	11	66	8
92	13	92	25
93	6	94	6
107	15	107	20
109	10	109	21
111	13	112	23
116	22	117	9

130	20	131	7
132	23	133	3
133	17	133	21
135	13	135	20
136	13	137	18
142	17	143	6
143	20	144	8
145	24	146	9
152	16	152	24
153	4	153	5
168	7	169	3
169	24	170	25
174	1	177	8
177	17	177	25
180	12	180	21

Lyle Brostrom			
August 28, 2007 (Takeda/TAP v. Teva)			
FROM		**TO**	
Page	**Line**	**Page**	**Line**
4	19	4	22
5	3	7	16
16	21	17	25
18	20	20	24
21	24	22	19
24	20	38	8
39	2	41	5
41	18	44	2
44	16	45	21
46	5	51	5
52	9	52	20
54	5	54	9
57	19	58	15
60	9	61	19
63	13	78	25
79	14	123	15

Gao Dong			
September 5, 2007 (Takeda/TAP v. Teva)			
FROM		**TO**	
Page	**Line**	**Page**	**Line**
6	16	10	22
11	22	12	4
12	14	13	25
14	12	18	23
20	4	20	11
20	18	20	25
23	8	23	21
26	23	27	20
28	9	28	11
31	5	32	2
32	7	32	22
38	8	38	25
40	9	40	13
41	13	41	24
44	19	45	2
48	12	48	24
54	23	57	4
57	18	57	25
60	21	61	19
61	25	62	15
63	21	64	9
65	2	65	15
69	23	70	10
75	19	76	7
79	11	79	19
83	8	85	4
88	11	90	7
93	13	94	19
102	20	103	24
106	12	107	13
110	5	111	10
117	20	118	8
124	5	124	14
129	21	131	3
137	6	138	11

EXHIBIT 10

DEFENDANTS' DEPOSITION COUNTERDESIGNATIONS FOR WITNESSES THAT WILL NOT TESTIFY AT TRIAL

Yoshitaka Maki			
January 30, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
47	3	47	20
47	24	48	1
48	9	48	12
50	4	50	4
50	10	50	17
52	23	52	23
53	8	53	15
114	10	114	17

Akira Nohara			
February 1, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
25	4	25	6
25	14	25	23
29	25	30	2
30	5	30	19
30	24	31	8
31	12	31	16
31	24	32	1
32	7	32	25
65	19	66	2
68	3	68	13

Simona DiCapua			
February 7, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
29	5	29	21
30	10	30	14
55	13	60	24
63	12	64	6
66	13	67	6
67	22	68	20
92	11	95	13
97	21	98	19
99	18	100	10
102	22	102	22
105	6	105	14
108	14	108	14
109	15	109	24
110	11	110	12
110	22	111	13

Philip Erickson			
Febraury 21, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
4	14	4	18
6	4	6	17
19	4	19	15
20	8	20	20
23	13	24	18
25	7	25	10
27	7	27	19
27	23	28	3
29	16	29	23
30	17	31	2
31	11	31	20

Philip Erickson			
Febraury 21, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
34	2	34	17
34	23	36	16
49	13	49	19
51	13	51	18
55	19	55	25
61	10	61	13
64	18	65	4

Hiroshi Satoh			
February 27, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
26	8	26	19
27	5	28	11
28	14	28	19
29	18	29	21
41	16	41	19
41	24	42	2
56	7	56	9
60	15	60	18
61	21	61	22
62	14	62	23
63	3	63	24
64	10	64	21
65	11	65	11
67	1	67	4
67	25	68	4
83	15	84	14
89	22	90	18
91	15	92	3
93	1	93	4

Hiroshi Satoh			
February 27, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
93	7	93	9

David Cole			
September 4, 2007 (Takeda/TAP v. Teva)			
FROM		TO	
Page	Line	Page	Line
19	15	21	3
21	19	22	17
27	15	27	15
30	6	31	3
53	14	53	15
54	22	55	3
55	8	56	8
56	14	57	23
61	20	63	9
63	12	63	13
63	15	64	24
65	14	65	15
65	25	66	2
67	2	69	3
69	11	69	15
69	21	69	21
69	23	70	19
71	13	72	21
81	22	82	10
113	20	114	18
124	23	125	10
148	23	149	4
149	12	149	12

EXHIBIT 11

EXHIBIT 11

PLAINTIFFS' STATEMENT OF INTENDED PROOF OF CLAIMS

A. The '098 Patent

1. The parties contest whether claim 10 of the '098 patent was obvious over the prior art available prior to August 16, 1984. In particular, Teva contends that claim 10 of the '098 patent was obvious in view of omeprazole.

2. Plaintiffs will show that Teva cannot prove that claim 10 of the '098 patent was obvious, and there is certainly not clear and convincing evidence of obviousness as required by law. It is undisputed that lansoprazole was a new compound in August 1984. It is undisputed that lansoprazole had not been described prior to August 1984. It is undisputed that lansoprazole is a useful pharmaceutical. Lansoprazole is one of only five known safe and effective proton-pump inhibitors ("PPIs"). Plaintiffs will show that one of skill in the art of PPIs in August, 1984 would not have found lansoprazole obvious in light of the prior art. There was no reason in August, 1984 for a person or ordinary skill to modify omeprazole, or any other prior art compound, to make lansoprazole. Moreover, the art was highly unpredictable and the critical aspects of the complex chemistry of PPIs were not known in August, 1984. One of ordinary skill in the art could not predict what choice of chemical substitutions would lead to a successful PPI that was active, stable and had few side effects.

3. The parties contest whether there is evidence of secondary considerations of non-obviousness of claim 10 of the '098 patent. Plaintiffs will show that secondary considerations of commercial success, failure of others, copying, initial skepticism and unexpected results further demonstrate that lansoprazole was not obvious.

4. The parties contest whether the '098 patent was procured by inequitable conduct. In particular, Teva contends that Takeda intentionally withheld additional experimental

results that are allegedly inconsistent with the results of experiments using the IMAU model presented in Table 1 of the '098 patent (Col. 6, ll. 5-28). Plaintiffs will show that the models used in those experiments are not comparable to the IMAU model disclosed in the '098 patent and are in any event not inconsistent or material to the results presented in the '098 patent. Plaintiffs will additionally show that there is no evidence that any individual at Takeda involved in the prosecution of the '098 patent intended to deceive the Patent Office.

B. The '321 Patent

5. The parties contest whether claim 2 of the '321 patent is infringed either literally or under the doctrine of equivalents by the products described in Teva's ANDA No. 77-255. In particular, Plaintiffs will show that the formulation of Teva's product meets each and every limitation of claim 2 of the '321 patent as properly construed.

6. The parties contest whether claim 2 of the '321 patent was obvious over the prior art available as of February 13, 1986. Plaintiffs will show that the invention claimed in claim 2 of the '321 patent would not have been obvious to a person of ordinary skill in the art in February, 1986. Prior to the invention of the '321 patent, there was no teaching or suggestion in the art that lansoprazole could be stabilized in a solid-state phase and *in vivo* using a basic inorganic salt and a coating agent. Plaintiffs will show that the prior art cited by Teva's experts does not teach or suggest the invention of claim 2 of the '321 patent, nor does the general knowledge within the art in February, 1986.

C. Injunction

7. The parties contest whether Plaintiffs will be irreparably harmed absent the grant of an injunction by the Court preventing Teva from marketing its proposed lansoprazole delayed release capsule products described in ANDA No. 77-255 before the expiration of the '098 and '321 patents. Plaintiffs will show that they will be irreparably harmed

by Teva's entry into the market and that Plaintiff will suffer damages in excess of Teva's resources to pay.

EXHIBIT 12

EXHIBIT 12

DEFNEDANTS' STATEMENT OF INTENDED PROOF OF CLAIMS

A. The '098 Patent

1. Teva will prove by clear and convincing evidence that claim 10 of the '098 patent was inherently anticipated and/or obvious in view of prior art as of August 16, 1984, the date on which the priority application was filed.

2. Claim 10 claims the molecular structure for the compound lansoprazole, one of a class of anti-ulcer drugs known as proton pump inhibitors ("PPIs"). Teva will show that the state of the prior art in the PPI field in August 1984, and long-recognized chemical properties of fluorine, render lansoprazole inherently anticipated and/or obvious to one of skill in the art. It is undisputed that the benzimidazole-methylsulfinyl-pyridine backbone structure common to PPI compounds (and first used in the PPI timoprazole in the 1970s) was known before August 1984. It is undisputed that Aktiebolaget Hässle developed and patented the prior art PPI compound omeprazole, the first commercially available PPI, prior to the development of lansoprazole. It is further undisputed that Byk Gulden developed and patented prior art PPI compounds using fluorinated substituents prior to the development of lansoprazole. Teva will show that one of ordinary skill in the art seeking to develop and market a PPI compound in August 1984 would have modified the prior art compounds to arrive at lansoprazole. Teva will make this showing using omeprazole, which was known at the time as the gold standard for PPIs, as the "lead compound." Teva also will show that the same result is achieved if the Byk Gulden or other compounds with the same basic structure are used as the "lead compound."

3. Plaintiffs will be unable to rebut Teva's prima facie case of obviousness through secondary considerations of non-obviousness, such as alleged commercial success, failure of others, copying, initial skepticism, and/or unexpected results.

4. Teva will prove by clear and convincing evidence that the ‘098 patent was procured by inequitable conduct. In support of the patentability of the ‘098 patent, Takeda submitted experimental data to the U.S. Patent and Trademark Office (“PTO”) from the indomethacin-induced antral ulcer rat model (“IMAU model”) purporting to show that lansoprazole was superior in potency to prior art compounds, including omeprazole and a specific Byk Gulden compound. (See ‘098 patent, col. 6, ll. 5-28.) Teva will show that Takeda intentionally withheld from the PTO experimental results from the IMAU model and other relevant testing models that are inconsistent with the data submitted to the PTO. This withheld data would have been considered highly material to the prosecution of the application by a reasonable Patent Examiner. The materiality of the intentionally withheld test results is underscored by the fact that Takeda submitted those results to the U.S. Food and Drug Administration when seeking approval to market lansoprazole commercially. Given Takeda’s undisputed knowledge of the inconsistent experimental results and Takeda’s decision to withhold such highly material information, Teva will show that it is proper to infer that Takeda had an intent to deceive the PTO.

B. The '321 Patent

5. Teva will prove that claim 2 of the '321 patent is not infringed, either literally or under the doctrine of equivalents, by the lansoprazole delayed-release products described in Teva's ANDA No. 77-255. In particular, Teva will show that its products do not contain the “pharmaceutical composition” required by claim 2 of the ‘321 patent. Defendants further will show that the benzimidazole compound (lansoprazole) and the basic inorganic salt (magnesium carbonate) in Teva’s products are not “in contact … evenly” as required by the language of claim 2 of the ‘321 patent.

6. Teva also will prove by clear and convincing evidence that claim 2 of the '321 patent was obvious in view of prior art as of February 13, 1986, the date on which the priority application was filed. Teva will show that the prior art cited by Teva's experts, and the general knowledge of those in the art in February 1986, taught that acid sensitive compounds, such as lansoprazole, could be stabilized in solid state and in acidic environments through the mixture of lansoprazole and basic inorganic salts of magnesium.

C. Injunction

7. Teva will demonstrate that an injunction by the Court preventing Teva from marketing the proposed lansoprazole delayed-release capsule products described in ANDA No. 77-255 before the expiration of the '098 and '321 patents is not warranted. First, an injunction is not warranted because, as explained above, Teva will show that it has not infringed valid and enforceable patents. Teva additionally will show that Plaintiffs will not be able to establish the factors for a permanent injunction discussed in eBay v. MercExchange, L.L.C., 126 S. Ct. 1837 (2006). Finally, Teva will show that any damages incurred due to sales of Teva's proposed products are calculable and would not exceed Teva's ability to pay them.

8. Teva will demonstrate that this is an exceptional case under 35 U.S.C. § 285, and Teva should be awarded attorneys' fees.